{"aid": "40017357", "title": "Biopharma Layoff Tracker 2024", "url": "https://www.biospace.com/article/biospace-layoff-tracker-2023-athenex-shutters-facility-cuts-staff/", "domain": "biospace.com", "votes": 2, "user": "robertn702", "posted_at": "2024-04-12 20:32:46", "comments": 0, "source_title": "Biopharma Layoff Tracker 2024: Genentech, Sanofi, Novartis and More Cut Staff | BioSpace", "source_text": "Biopharma Layoff Tracker 2024: Genentech, Sanofi, Novartis and More Cut Staff | BioSpace\n\nWe use cookies to give you a better BioSpace experience. By continuing to use\nour site, you are agreeing to the use of cookies as set in our Privacy Policy.\n\nAccept\n\nSkip to main content\n\n  * Skip to main menu\n  * Skip to user menu\n\n## Filter News\n\n  * All (808,008)\n  * Topic (765,958)\n  * Hotbed/Location (736,153)\n  * Career Advice (3,895)\n  * Insights (177)\n  * Webinars (8)\n  * Podcasts (38)\n\n# Biopharma Layoff Tracker 2024: Genentech, Sanofi, Novartis and More Cut\nStaff\n\nPublished: Apr 11, 2024 By Neil Versel\n\n2023 was a tough year for the biopharma industry, with several companies\ndownsizing and restructuring their workforces to stay afloat. There are signs\nof recovery, as mergers and acquisitions picked up across the pharmaceutical\nand life sciences industry in the latter part of 2023 and have continued their\nupswing into 2024. Will the job market follow suit?\n\nBioSpace will continue to be your source of news on job cuts and restructuring\ninitiatives throughout 2024. Follow along as we keep you up to date on which\ncompanies are tightening their belts and cutting staff.\n\n## April\n\nApril 11\n\nGenentech will reduce its workforce by about 3% across multiple departments, a\ncompany representative confirmed in an email to BioSpace. According to\nGenentech\u2019s website, the firm has about 13,500 employees, suggesting that\nthere will be about 405 cuts. The spokesperson said that there will be no net\nworkforce reductions at parent company Roche.\n\nApril 10\n\nSanofi will eliminate 100 jobs on June 3 from a San Francisco site as part of\na planned divestiture of Amunix Pharmaceuticals, an immuno-oncology company it\nbought for $1 billion in 2021, according to a WARN notice first reported by\nEndpoints News.\n\nThe cuts follow news from April 4 that Sanofi will cut an unspecified number\nof jobs as part of a \u201cfull pipeline reprioritization\u201d effort, R&D chief Houman\nAshrafian told staff in an email obtained by Fierce Biotech. The French pharma\ngiant is shifting its R&D toward immunology, as evidenced by its pending $2.2\nbillion acquisition of Inhibrx.\n\nApril 9\n\nNovartis is continuing its deep workforce cuts by announcing plans to\neliminate about 680 jobs in product development over the next two to three\nyears, with about 440 of those currently based in Switzerland and the other\n240 in the U.S., according to Reuters. Many of those jobs will be shifted to\nother \"established hubs\" over the next two years, a Novartis spokesperson told\nBioSpace, resulting in a net reduction of 1% to 2% in the company's global\ndevelopment workforce, which now stands at about 12,500. Reuters reported that\nthe new downsizing is separate from a two-year-old restructuring program that\ncould ultimately cost as many as 8,000 people their jobs.\n\nCorrection (April 10): This story has been updated from its original version\nto reflect the proper percentage of jobs that are being cut, BioSpace regrets\nthe error.\n\nApril 4\n\nCiting slow uptake of its Humira biosimilar Cyltezo (adalimumab-adbm),\nBoehringer Ingelheim is cutting its customer-facing salesforce. While the\ncompany did not disclose the number of layoffs, Stat News reported that about\n70 employees are losing their jobs, citing an anonymous source.\n\nApril 4\n\nAs a result of its decision to pull ALS drug Relyvrio from the U.S. and\nCanadian markets following a Phase III trial failure, Amylyx Pharmaceuticals\nwill downsize its workforce by about 70%. The company disclosed in a\nregulatory filing that it had 384 employees at the end of 2023.\n\nApril 3\n\nThermo Fisher Scientific will eliminate 74 jobs at its plasmid DNA\nmanufacturing site in Carlsbad, Calif., starting May 31, Fierce Pharma\nreported. The facility opened less than three years ago.\n\nApril 1\n\nCarisma Therapeutics disclosed in its Q4 financial release that will cut its\nworkforce by 37% in Q2 as part of a restructuring that will shut down\ndevelopment of its former lead candidate, CT-0508, a targeted CAR-M for\ntreatment of advanced and metastatic cancers with overexpressed HER2. Though a\nPhase I trial of CT-0508 met its primary endpoints, Carisma will prioritize\nCT-0525, a CAR-monocyte, for development of an anti-HER2 therapy.\n\n## March\n\nMarch 28\n\nOmega Therapeutics said in its Q4 financial release that it has cut\napproximately 35% of its workforce following a strategic review of its\nbusiness. The company will prioritize its preclinical programs, including\nOTX-2101 for non-small cell lung cancer, an HNF4A agent for fibrotic liver\ndisease and a partnership with Novo Nordisk to develop an epigenomic\ncontroller to target obesity. Omega disclosed in a regulatory filing that it\nhad 93 full-time employees at the end of 2023.\n\nMarch 28\n\nXilio Therapeutics announced it is cutting 15 jobs, or about 21% of its\ncurrent workforce as part of a \u201cstrategic portfolio reprioritization.\u201d The\nlayoffs coincide with a $113 million private placement as well as a deal for\nGilead Sciences to license Xilio\u2019s XTX301, a tumor-activated IL-12 and XTX101,\na tumor-activated, Fc-enhanced CTLA-4 inhibitor, for $43.5 million upfront and\nfuture contingent payments of as much as $604 million.\n\nMarch 27\n\nBayer revealed in a WARN notice that it will lay off 90 workers at its U.S.\nheadquarters in Whippany, N.J., effective June 19, Fierce Pharma reported. The\nmove comes just a week after Bayer cut several top executives their jobs as\npart of a reorganization announced in January.\n\nMarch 26\n\nBristol Myers Squibb disclosed in a WARN notice in California that it is\nletting go 252 workers at the former Mirati Therapeutics headquarters in San\nDiego, effective April 22. Fierce Pharma first reported the notice. BMS\ncompleted its $4.8 billion acquisition of Mirati Jan. 23.\n\nMarch 22\n\nTheratechnologies is eliminating an unspecified number of jobs as it phases\nout preclinical oncology research activities in favor of an in-progress Phase\nI trial of its peptide-drug conjugate sudocetaxel zendusortide (TH1902) for\nadvanced ovarian cancer. The company said that it will absorb $625,000 in cash\ncharges to cover severance and related expenses, as well as $770,000 in non-\ncash charges as part of the restructuring. Last month, the FDA refused to\nreview Theratechnologies\u2019 supplemental Biologics License Application for a new\nformulation of the HIV therapy Trogarzo.\n\nMarch 21\n\nGSK will be cutting loose the majority of its former Bellus Health employees\non March 31, according to a LinkedIn post from ex-Bellus CEO Roberto Bellini.\nGSK bought Bellus a year ago for $2 billion, largely to acquire the latter\u2019s\nPhase III candidate camlipixant, a P2X3 receptor antagonist proposed to treat\nchronic cough. In December, competitor Merck for the second time failed to\ngain FDA approval for its own P2X3 candidate, gefapixant.\n\nMarch 21\n\nNextCure disclosed in a regulatory filing that it is cutting its workforce to\n51 full-time employees from the current 81, a reduction of 37%. To save cash,\nthe company will focus on its NC410 candidate combination therapy for ovarian\nand colorectal cancers and LNCB74, an ADC that targets B7-H4 and is being\ndeveloped in collaboration with LegoChem Biosciences. NextCure will pause\ndevelopment of its other assets as the company seeks partners or buyers to\nadvance them.\n\nMarch 21\n\nCatalent will lay off 130 workers at one of its manufacturing sites in\nBloomington, Ind. According to The Herald-Times, the manufacturer said it will\ncut jobs to \u201cincrease efficiencies\u201d and \u201clower costs\u201d but provided no details\non what positions will be axed or further explanations on the move. This is\nnot the first time Catalent has undertaken layoffs at its Bloomington\nfacility, as the CDMO laid off hundreds of employees in 2022 and 2023. Just\nlast month, Novo Nordisk agreed to acquire Catalent for $16.5 billion, and the\nBloomington facility will soon be sold to Novo Nordisk to boost GLP-1\nmanufacturing capabilities.\n\nMarch 20\n\nBayer has trimmed its executive team to eight people, down from 14, as part of\na major operating overhaul announced in January. Among those out of work are\nAnne-Grethe Mortensen, head of global marketing; Gerd Kr\u00fcger, head of\nradiology; and Heiko Schipper, president of the company\u2019s consumer health\ndivision. CMO Michael Devoy will retain his role but will no longer be part of\nthe leadership team.\n\nMarch 13\n\nSpruce Biosciences has cut 21% of its workforce as part of a round of cost\nreductions that includes the shutdown of its CAHmelia-203 clinical trial, the\ncompany announced in its 2023 fourth quarter financial report. In a separate\npress release Thursday, Spruce revealed that the trial of its oral CRF1\nantagonist tildacerfont failed in the treatment of adult classic congenital\nadrenal hyperplasia.\n\nMarch 13\n\nCoherus BioSciences is cutting its workforce by 30% as part of a restructuring\nthat will result in a greater focus on oncology, the biotech announced\nThursday in its 2023 fourth quarter financial results and business update. The\nfirm completed the $170 million sale of its ophthalmology business to Sandoz\non March 1, though the current round of layoffs did not begin until March 7.\n\nMarch 12\n\nTakeda Pharmaceuticals is shutting down R&D and manufacturing operations at a\nfacility in Orth an der Donau, Austria, cutting 190 jobs in the process,\nEndpoints News reported, citing Austrian newspaper Kronen Zeitung. About 140\npeople will remain at the site in quality control as Takeda seeks to sell the\nproperty, which it picked up when it acquired Shire in 2019.\n\nMarch 12\n\nInnovent Biologics eliminated its entire research team at its U.S.\nheadquarters and wet lab in Rockville, Md., near the end of February and will\nclose the facility in the near future, BioSpace first reported. The Suzhou,\nChina\u2013based biotech conducted mostly ADC research at the Washington, D.C.\u2013area\nlab.\n\nMarch 11\n\nSanofi is closing a former Kymab R&D facility in Cambridge, U.K., according to\nCambridge publication BusinessWeekly. While the Big Pharma firm said it will\ntry to find homes elsewhere in the company for the 90 affected employees,\nthere could be layoffs. Sanofi acquired Kymab for $1.4 billion in 2021.\n\nMarch 7\n\nKronos Bio is cutting 21% of its workforce as part of a corporate\nrestructuring that the company said would extend its cash runway into late\n2026. Kronos\u2014which currently has about 100 employees, according to Yahoo!\nFinance\u2014announced in December that a key trial had failed in Phase Ib.\n\nMarch 5\n\nSumitomo Pharma will lay off approximately 400 staff in order to pare down its\nNorth American business operations following disappointing sales of three of\nits drugs, the company announced Monday. In a subsequent announcement,\nSumitomo detailed what it called an organizational alignment, including the\ndissolution of its CNS sales department and the departures of its managing\nexecutive officer and two executive officers. Current Vice President Yutaka\nWakemi will assume the post of executive officer on April 1.\n\nThe cuts follow an earlier layoff of 62 employees in Sumitomo's New York\noffices in July 2023.\n\nMarch 5\n\nMeissa Vaccines is halting plans to launch a Phase II/III clinical study of\nits MV-012-968 intranasal RSV vaccine due to funding shortfalls, causing an\nunspecified number of layoffs, FierceBiotech reported. CEO Frank Glavin\nindicated that Meissa would \u201creview its strategic options\u201d in light of this\nfunding issue, putting the future of the company in doubt.\n\nMarch 4\n\nChemical conglomerate and CDMO Evonik Industries will eliminate as many as\n2,000 jobs from its global workforce by 2026, Reuters reported. That\nrepresents 32% of the German firm\u2019s current workforce of more than 6,200.\n\nMarch 1\n\nPfizer will cut 120 jobs as part of its decision to end construction on a\nplanned $350 million, 270,000-square-foot manufacturing plant in Everett,\nWashington, according to reports from Puget Sound Business Journal and\nGeekWire. Pfizer, which acquired Seagen for $43 billion last year, will\nreportedly shift most of the manufacturing planned for the Seattle-area\nfacility to an existing site in Sanford, North Carolina.\n\nMarch 1\n\nArrakis Therapeutics is cutting about 20% of its staff, Endpoints News\nreported. The startup biotech, which is developing targeted RNA degrader\ntherapeutics, had nearly 100 employees as of August 2023.\n\nMarch 1\n\nModerna has laid off an unspecified number of manufacturing and quality-\nassurance workers in its Burlington and Norwood, Massachusetts, facilities,\nEndpoints News reported. The mRNA vaccine maker attributed the cuts to\npreviously announced lower demand for COVID-19 shots, though the firm said\njust last week that it has completed construction on a new mRNA manufacturing\nfacility in Quebec.\n\n## February\n\nFeb. 29\n\nKineta announced a corporate restructuring that has resulted in the\nelimination of seven jobs, or 64% of its current workforce. Among those losing\ntheir jobs is CEO Shawn Iadonato, though he has been retained as a consultant\nthrough the end of the year as the firm considers a sale, acquisition,\nliquidation or other alternative. Kineta has also stopped enrolling patients\nin its VISTA-101 Phase I/II trial for its KVA12123 compound for advanced solid\ntumors.\n\nFeb. 29\n\nGritstone Bio announced it is trimming its workforce by about 40% following\nthe delay of its planned Phase IIb study for a self-amplifying mRNA COVID-19\nvaccine, which cost the company funding from the U.S. Biomedical Advanced\nResearch and Development Authority (BARDA) to support the research. Gritstone\nsaid the study will now launch in the fall of 2024 as opposed to the\noriginally planned Q1 start.\n\nFeb. 28\n\nSwiss biotech ObsEva announced plans to shut down completely and terminate all\nits employees. The troubled clinical-stage firm focused on women\u2019s health had\nas few as 15 employees, according to various online trackers.\n\nFeb. 27\n\nPerrigo disclosed in its 2023 fourth-quarter financial report that it was\ncutting about 6% of its workforce as part of a restructuring plan. The company\ncurrently employs approximately 9,000 people worldwide, according to its\nwebsite, meaning that more than 500 workers will lose their jobs.\n\nFeb. 26\n\nDenali Therapeutics is laying off an unidentified number of employees,\naccording to a Fierce Biotech report on Monday. This comes after a Phase II\ntrial of a Denali and Sanofi-partnered ALS candidate did not reach its primary\nendpoint in Phase II, which was disclosed in an SEC document earlier in\nFebruary. According to Fierce, the exact number of workers affected was not\ndisclosed. However, a Denali spokesperson told the outlet that the layoffs\nconstitute \u201cconsiderably less\u201d than 10% of its workforce.\n\nJan. 22\n\nGalapagos NV announced in its full-year results for 2023 that it has\n\u201cstreamlined\u201d its operations and reduced around 100 positions across the\nboard. The company said in a statement that this staff reduction is to \u201calign\nwith the Galapagos\u2019 renewed focus on innovation.\u201d However, no details were\ngiven on where the positions were cut or exactly when they occurred. Galapagos\nis also halting the development of its CD19 CAR-T candidate in refractory\nsystemic lupus erythematosus \u201cfor strategic reasons,\u201d the Belgian biotech\nsaid.\n\nFeb. 21\n\nAdaptive Biotechnologies has cut 6.7% of its workforce as part of a \u201cstrategic\nreview,\u201d Endpoints News reported. The exact number of lost jobs was not\ndisclosed. The company last downsized its workforce in March 2022.\n\nFeb. 20\n\nRing Therapeutics has eliminated 19 jobs, or nearly 20% of its workforce,\naccording to STAT News. The gene therapy startup, founded by Flagship\nPioneering, raised an $86.5 million Series C round less than a year ago.\n\nFeb. 16:\n\nKenvue is cutting 51 jobs in New Jersey and 84 in California, according to\nFiercePharma. The former consumer health division of Johnson & Johnson, Kenvue\nwas spun off from the core pharmaceutical business in mid-2023.\n\nFeb. 16:\n\nSonata Therapeutics has eliminated 21 jobs, or one-third of its approximately\n63 employees, STAT News reported Friday, citing social media posts and a\ncompany spokesperson. The startup, a combination of two Flagship Pioneering\ncompanies, focuses on the role of cellular microenvironments in causing\ndisease.\n\nFeb. 15:\n\nAurinia Pharmaceuticals announced plans to cut at least 25% of its workforce\nthis quarter after the company failed to find a buyer, Fierce Biotech\nreported. The Canadian biotech firm is trimming its drug pipeline, eliminating\nwork on its AUR200 compound for B-cell mediated autoimmune conditions and its\nAUR300 M2 macrophage regulator.\n\nFeb. 14:\n\nCatalent has reduced its headcount by an additional 300 in the 2023 fourth\nquarter as part of an ongoing restructuring effort, the company disclosed in a\nregulatory filing. This followed a Dec. 8 announcement that Catalent had\nreduced its workforce by 1,100 to that date. Catalent is in the process of\nbeing acquired by Novo Nordisk for $16.5 billion.\n\nFeb. 13:\n\nLianBio is laying off more than 50 full-time employees, or half of its current\nworkforce, as the company begins to wind down its operations, according to a\nFeb. 13 LianBio press release. The Chinese biotech will voluntarily delist\nfrom the Nasdaq around March 18 and expects to dissolve by 2027, the company\nsaid.\n\nFeb. 9:\n\nRoche will be cutting 345 jobs, according to the Swiss business news site\nMuula. According to the Muula report, the layoffs affect the Basel-based\npharma\u2019s product development division and account for 6% of the workforce in\nthis division. A Roche spokesperson told Reuters that the job cuts would\nactually be fewer than 345 but did not give an exact figure.\n\nFeb. 9:\n\nSandoz will be shutting down one of its sites in North Carolina and axing 213\npositions along with it, according to the WARN summary issued by the state.\nThe site in question is Eon Labs, a generic manufacturer based in Wilson. A\nSandoz spokesperson told Fierce Pharma that the site is closed due to \u201cprice\nerosion\u201d in the generics sector. Sandoz acquired Eon Labs in 2005 and\nsubsequently folded it into its generics division.\n\nFeb. 9:\n\nSynlogic will be cutting 90% of its staff, including CEO Aoife Brennan. The\nlayoffs come as the company decides to halt any future work in its Synpheny-3\nstudy on its treatment candidate SYNB1934 (labafenogene marselecobac) for\nphenylketonuria.\n\nAccording to a company release, Synlogic is halting the trial due to the\nfindings of an independent data monitoring committee that the trial would not\nmeet its primary endpoint. The biotech is now working with clinical trial\nsites to execute the discontinuation while the board will \u201cevaluate strategic\noptions\u201d for the company, the release stated. These options may include an\nacquisition, merger, sale of its assets, dissolution or reverse merger, among\nother possibilities.\n\nFeb. 6:\n\nRallybio Corporation is laying off nearly half of its workforce\u201419 people\u2014in a\nbid to extend its cash runway into 2026, the New Haven\u2013based biopharma\nannounced Tuesday. According to the announcement, Rallybio will now prioritize\ndevelopment of two Phase II candidates, a monoclonal antibody to prevent fetal\nand neonatal alloimmune thrombocytopenia, and an injected inhibitor designed\nto treat patients with complement-mediated diseases.\n\n## January\n\nJan. 31:\n\nAfter struggling as a pandemic player, Novavax last year embarked on a company\ntransformation. Part of that overhaul will involve a global workforce\nreduction of approximately 12%, the company announced on Wednesday. The move\nfollows Novavax\u2019s May 2023 decision to cut 25% of its workforce. Once the\nlayoffs are complete, the company expects to have 30% fewer employees than it\ndid at the end of the first quarter in 2023, according to the press release.\n\nAccording to Novavax, the transition will allow the company to bring its\nCOVID-19-influenza combination vaccine into Phase III. President and CEO John\nC. Jacobs said Novavax is \u201cpurposefully focusing only on the critical\nactivities needed to achieve our objectives and strengthen the financial\nperformance of the Company.\u201d\n\nJan 30:\n\n2seventy Bio is making some significant changes. The company will sell its\nresearch and development pipeline to Regeneron and cut 55 staff members,\naround 45% of its remaining personnel, Endpoints News reported Tuesday.\nRegeneron will acquire all of 2seventy Bio\u2019s R&D infrastructure and employees,\nincluding 160 people, as well as CSO Philip Gregory, who will be the head of\nRegeneron\u2019s new cell medicines unit, according to Endpoints. The deal will see\nRegeneron pay $5 million upfront to 2seventy Bio, along with a single\nmilestone payment and eventual royalty payments. According to Endpoints, the\nbiotech will now focus on commercializing a CAR-T cell, Abecma, developed with\nBMS. Meanwhile, 2seventybio CEO Nick Leschly will become board chairman, while\nCOO Chip Baird will assume the CEO post.\n\nJan. 29:\n\nCell therapy biotech Catamaran Bio is ceasing operations, according to a post\nby CEO Alvin Shih on LinkedIn. Shih said the \u201cdifficult decision\u201d has been\nmade to suspend day-to-day operations while the company looks to \u201cpursue\nstrategic options.\u201d He said the company still believes in its allogenic\ntherapeutics but noted the challenging state of the financing environment for\nearly-stage companies in the cell therapy arena. Catamaran will seek strategic\npartners for its CAR NK cell therapy candidates, Endpoints News reported. The\ncompany had 19 employees as of Monday, Shih told Endpoints, adding that a\n\u201chandful\u201d will stay on for a transition period.\n\nJan. 29:\n\nBig pharma giveth and big pharma taketh away. Fifteen months after inking a\nlucrative licensing an R&D collaboration with Roche focused on its HB-700 KRAS\nprogram, Hookipa Pharma revealed Monday that the Swiss pharma had terminated\nthe agreement. In the same business update, Hookipa announced it will cut\napproximately 30% of its workforce in a cost-saving initiative. The New York\nand Vienna\u2013based company said it plans to submit an Investigational New Drug\napplication for HB-700 in the first quarter of this year and will begin the\nsearch for a new collaboration partner. Separately, Hookipa will pause\ndevelopment on prostate cancer asset HB-300 and most preclinical research\nactivities, according to the business update.\n\nJan. 29:\n\nPfizer\u2019s cost-cutting campaign continues as the company plans to lay off 52\nemployees at a facility in South San Francisco, Fierce Pharma reported Monday,\nciting a recent WARN alert. The layoffs are to take effect in mid-February.\nAccording to Fierce, the address listed on the WARN report matches the former\nheadquarters of Global Blood Therapeutics, which Pfizer acquired in 2022 for\n$5.4 billion. Pfizer launched a sweeping cost-cutting initiative in October\n2023, aiming to generate $3.5 billion in savings through 2024 as it weathers a\nsteep decline in sales of its COVID-19 products. Since then, the move has\naffected employees in Groton, Connecticut; Kalamazoo, Michigan; and Kent, U.K.\n\nJan. 26:\n\nBoston\u2013based programmable RNA startup Strand Therapeutics has laid off around\n18% of its staff, Endpoints News reported Friday. The layoffs affect 19 of\nStrand\u2019s 108 employees who worked on its earliest stage programs, the company\ntold Endpoints.\n\n\u201cWe\u2019re moving from platform to pipeline,\u201d Strand CEO Jake Becraft told the\npublication. \u201cSome of the tools we had been building over the last year or\ntwo, even though successful in the research, are not going to be needed in\nthose drug products.\u201d\n\nThis news follows Strand\u2019s announcement on Monday that the FDA has cleared a\nPhase I trial for STX-001, an mRNA-based cancer therapy that triggers\nproduction of the inflammatory protein IL-12 for an extended period of time\ndirectly into the tumor microenvironment.\n\nJan. 22:\n\nStamford, CT-based Cara Therapeutics will lay off about half of its employees,\nthe company announced on Monday, including CSO Fr\u00e9d\u00e9rique Menzaghi. The move\ncomes hand in hand with the shuttering of its Phase III chronic kidney disease\nprogram and is expected to extend Cara\u2019s cash runway into 2026. The\nbiotech\u2014which had 106 employees as of March 2023, Endpoints News reported\u2014will\nnow shift its focus to investigating difelikefalin in patients with the\nneuropathic disorder notalgia paresthetica (NP) after oral difelikefalin\nfailed to show meaningful clinical benefit in patients with atopic dermatitis.\n\nJan. 18:\n\nIkena Oncology is laying off approximately 35% of its workforce as part of \u201can\norganizational streamlining that allows for the reallocation of resources from\nexploratory research and discovery towards the ongoing targeted oncology\nclinical programs,\u201d the company announced Thursday. According to an SEC\nfiling, about 20 employees will be let go from the Boston\u2013based company, with\n37 remaining. The filing also notes that on January 17, Bristol Myers Squibb\nnotified Ikena that it would not continue a collaboration the two companies\nhad around two drug candidates. In its announcement, Ikena said it will now\nfocus exclusively on its two lead, clinical-stage oncology candidates, and\nthat its cash runway extends into the second half of 2026.\n\nJan. 18:\n\nPMV Pharmaceuticals is laying off approximately 30% of its staff in order to\nextend its cash runway to the end of 2026, the company announced Thursday.\nAccording to its LinkedIn page, the New Jersey\u2013based company has between\n51-200 employees. PMV said its priority is development of its candidate\nPC14586, a small molecule p53 reactivator now in clinical trials to treat\nsolid tumors with a specific mutation.\n\nJan. 17:\n\nBayer unveiled a new operating model on Wednesday that will involve an\nunspecified number of layoffs. Barbara Gansewendt, chairwoman of the company's\nGroup Executives\u2019 Committee, said in a statement that the move \u201cwill come at\nthe expense of many managerial employees.\u201d As of the end of last year, Bayer\nhad 101,000 employees worldwide.\n\nJan. 17:\n\nLonza will cut 218 jobs at its Hayward, California site, according to a WARN\nreport. The company reported that it is closing its manufacturing facility\nthere. The layoffs will take effect Feb. 2, with the plant closing in the\nfirst quarter of 2025, a company spokesperson told Fierce Pharma.\n\nJan. 16:\n\nDewpoint Therapeutics is cutting approximately 20 positions, or 15% of its\nstaff, as a couple of pharma collaborations fell through, CEO Ameet Nathwani\ntold STAT News. The move is intended to free up cash to onboard new hires who\nwill focus on growing the company\u2019s AI platforms and bringing its first drugs\ninto clinical trials, according to STAT.\n\nJan. 16:\n\nAllakos, Inc. is ending work on its candidate lirentelimab after disappointing\nPhase II results in atopic dermatitis and chronic spontaneous urticaria and\nlaying off about 50% of its workforce, the company announced Tuesday. The San\nCarlos, California\u2013based company has 123 employees, according to GlobalData.\nAllakos said the restructuring will extend its cash runway into 2026 and that\nit will now focus on its monoclonal antibody AK006, which was engineered to\ninhibit mast cells and is now in Phase I testing in healthy volunteers.\n\nJan. 9:\n\nC4 Therapeutics will lay off about 30% of its staff, or 45 people, in a bid to\nextend its cash runway into 2027, the company announced Tuesday. The company\nsaid it will prioritize development of its clinical-stage candidates CFT7455,\nCFT1946 and CFT8919, all of which are aimed at treating cancers. \u201cOur\nstrengthened balance sheet, coupled with cost savings from our restructuring,\nprovide sufficient runway to execute through and beyond critical milestones\nacross the portfolio,\u201d said Andrew Hirsch, C4 president and CEO, in the\ncompany\u2019s announcement.\n\nJan. 8:\n\nGerman immuno-oncology company Affimed is cutting its headcount by up to half,\nit announced Monday. The company said the restructuring will direct all of its\nresources into its clinical-stage programs and extend its cash runway into\n2025. Affimed announced last week that it is selling its subsidiary AbCheck.\nAs of the end of March 2023, Affimed had 219 full-time employees, the company\nstated in an annual report.\n\nAffimed CEO Adi Hoess, who has held the position for 13 years, will step down\neffective Jan. 15, according to the announcement, and Chief Medical Officer\nAndreas Harstrick will serve as interim CEO.\n\nJan. 5:\n\nSenti Biosciences will lay off about 37% of its workforce, the South San\nFrancisco\u2013based company announced on Friday. Senti, which recently received\nInvestigational New Drug approval from the FDA for its cell-based treatment\nfor acute myeloid leukemia, said in the announcement that it will focus its\nresources on that candidate and on developing a treatment for a form of\nhepatocellular carcinoma. It expects that its cash runway will now be extended\ninto the first quarter of next year.\n\nAccording to its LinkedIn page, Senti has between 51\u2013200 employees.\n\nJan. 5:\n\nAllogene Therapeutics will cut nearly a quarter of its workforce as it shifts\nfocus to developing its blood cancer therapy, Reuters reported Friday. The\nSouth San Francisco\u2013based company recently announced it no longer focus on two\nstudies testing another blood cancer therapy Cema-Cel, according to Reuters.\nAllogene had 361 employees as of February 2023.\n\nJan. 4:\n\nIntellia Therapeutics is laying off approximately 15% of its workforce and\npausing select exploratory research-stage programs, the gene editing company\nannounced Thursday. The cuts will take place across all departments, a company\nrepresentative told Endpoints News, and \u201cwon\u2019t impact its lead programs and\ncandidates.\u201d\n\nIntellia made the announcement in a press release highlighting the company\u2019s\nthree-year strategic priorities and 2024 key milestones, which include dosing\nthe first patient in the MAGNITUDE trial of NTLA-2001 in ATTR amyloidosis with\ncardiomyopathy in Q1 of this year and preparing for the Phase III study of\nNTLA-2001 in ATTR amyloidosis with polyneuropathy.\n\nAs of Feb. 17, 2023, Intellia had 598 full-time employees, 471 of whom were\nprimarily working in R&D, according to an SEC filing.\n\nJan. 4:\n\nThermo Fisher Scientific is closing its site in Petaluma, Calif., and will\npart with 74 of the facility\u2019s employees, according to a WARN notice,\nEndpoints News reported. Thermo Fisher\u2019s 10-year lease at the 89,649-square-\nfoot facility\u2014which makes pipette tips, microcentrifuge tubes and\nracks\u2014expires in July, according to the North Bay Business Journal.\n\n\u201cDecisions that impact colleagues and their families are never taken lightly,\"\na company spokesperson told San Francisco Business Times in an email. \"All\nimpacted colleagues will receive job transition support to aid them in finding\nnew opportunities.\u201d\n\nJan. 4:\n\nAera Therapeutics, which launched in February 2023 with $193 million in\ncombined Series A and Series B funds to \u201cenable and advance the next\ngeneration of transformative genetic medicines,\u201d has laid off 25% of its\nstaff, STAT News reported.\n\nIn a statement, spokesman Dan Budwick blamed a difficult biotech funding\nenvironment for the cuts. \u201cAlthough Aera remains in a strong cash position\ntoday, given the current biotech funding environment, we have chosen to take\nsteps to focus our strategy and investments on the development of our novel\ndelivery platforms, thereby further extending our cash runway,\u201d he said,\naccording to STAT.\n\nFounded by world-renowned scientist Feng Zhang, Aera is attempting to deliver\nCRISPR enzymes and other gene-editing or gene-modulation tools to specific\ncells and organs in the body.\n\nJan. 1:\n\nOn Dec. 22, 2023, AlloVir announced it would discontinue its three Phase III\nstudies of posoleucel, an investigational T cell therapy, after DSMB futility\nanalyses concluded the trials were unlikely to meet their primary endpoints.\nThe Waltham, Mass.\u2013based company has now revealed it will part ways with\napproximately 95% of its staff \u201cin order to reduce costs and preserve\ncapital,\u201d according to a WARN report dated Jan. 1. The layoffs will primarily\ntake place during the first quarter of this year. The company had 114\nemployees as of Sept. 30, 2023, according to an SEC filing.\n\n## December\n\nDec. 19:\n\nFollowing the Phase II failure of its lead asset last month, Aclaris\nTherapeutics is laying off 46% of its workforce, the company announced\nTuesday. The company will cease development of zunsemetinib (ATI-450) for\nimmuno-inflammatory disease indications after the failure but will explore its\nuse in some cancers, according to the announcement, along with continuing to\ndevelop other candidates in its pipeline.\n\nThe Pennsylvania-based Aclaris had 100 employees as of the end of 2022,\naccording to an SEC filing.\n\nDec. 19:\n\nImmunotherapy company Asher Bio has laid off 34 people\u201460% of its\nworkforce\u2014and is narrowing its focus to a single drug candidate, Fierce\nBiotech reported Tuesday. That asset, AB248, is now in Phase I testing for\nsolid tumors in combination with Keytruda.\n\nThe South San Francisco\u2013based Asher emerged from stealth in 2021 and announced\n$108 million in Series B financing later that year.\n\nDec. 18:\n\nAtara Biotherapeutics is laying off 73 employees in Thousand Oaks, California,\naccording to a WARN notice reported by Endnotes News on Monday. The\nimmunotherapy company had announced plans on November 1 to reduce its\nworkforce by approximately 30%; a week later, its stock price plunged\nfollowing the announcement that a Phase II trial of its candidate for multiple\nsclerosis had failed.\n\nDec. 14:\n\nFollowing the Phase II failure of its investigational treatment for a group of\nrare genetic disorders, Reneo Pharmaceuticals will lay off 70% of its\nworkforce, the company announced Thursday. According to an SEC filing, as of\nMarch 2023 Reneo had 48 employees, 36 of them full-time.\n\nReneo had been testing a peroxisome proliferator-activated receptor delta\n(PPAR\u03b4) agonist called mavodelpar in people with metabolic disorders known as\nprimary mitochondrial myopathies, but the therapy met neither its primary nor\nits secondary endpoints. The company is now discontinuing development of\nmavodelpar. Its stock price fell by 87% following the news, Fierce Biotech\nreported.\n\nDec. 13:\n\nImmunology company Vir Biotechnology will lay off 12% of its\nworkforce\u2014approximately 75 positions\u2014and shutter its R&D facilities in St.\nLouis, Missouri, and Portland, Oregon, next year, the company announced\nWednesday. \u201cWhile these decisions are difficult, they will enable us to\nprioritize investment in the clinical execution of our chronic hepatitis delta\nand chronic hepatitis B programs, as well as on broadening the long-term\napplicability of our world-class monoclonal antibody platform beyond\ninfectious diseases to autoimmune diseases and oncology,\u201d said Vir CEO\nMarianne De Backer in the company\u2019s statement.\n\nVir had entered into a research and development partnership with GSK in April\n2020 for COVID-19. But the companies\u2019 Sotrovimab treatment lost FDA\nauthorization two years later, and in February of this year, GSK stepped back\nfrom the coronavirus portion of the partnership while staying engaged with Vir\non the development of a new flu shot and other respiratory virus programs. In\nJuly of this year, the flu vaccine candidate failed a Phase II trial.\n\nDec. 13:\n\nXellia Pharmaceuticals, a manufacturer of anti-infective treatments and\ncritical care therapies owned by Novo Holdings, will lay off 80 employees at\nits Bedford, Ohio, plant, according to a WARN notice reported by Fierce\nPharma. Fierce notes that the plant, located just outside Cleveland, was\nreopened in 2021 after a change of ownership and a $200 million revamp. The\nsite had about 300 employees at the time.\n\nDec. 11:\n\nAltamira Therapeutics has reduced its headcount by about 25% as part of a\n\u201cstreamlining\u201d process, the company announced yesterday. Altamira has been\nshedding what it calls its legacy assets as it aims to focus exclusively on\nRNA delivery. The Bermuda-based company has between 11 and 50 employees,\naccording to its LinkedIn page.\n\nDec. 8:\n\nCatalent Pharma Solutions has cut 1,100 jobs this year, the company revealed\nin an annual report released Friday. The cuts, made mostly in the biologics\nand corporate divisions, came amid revenue losses of $539 million.\n\nDec. 7:\n\nFerring Pharmaceuticals will lay off 55 employees in Minnesota and 79 in New\nJersey in the coming months, according to WARN notices and reporting by KSTP-\nTV. A company spokesperson told the station that the Roseville, Minnesota,\ncuts affect about a quarter of positions at that site.\n\nDec. 5:\n\nIGM Biosciences is laying off approximately 22% of its employees, the company\nannounced Tuesday. The restructuring will extend the biotech\u2019s cash runway\ninto 2026 as it prioritizes candidates for colorectal cancer and autoimmune\ndisease, according to the announcement, while discontinuing programs in\nhematologic oncology and targeted cytokine products.\n\n\u201cAlthough we are very encouraged by the clinical and preclinical data that we\nhave generated for the programs we are halting, given the difficult conditions\nin the capital markets for our industry, we have decided to focus our capital\nresources on those opportunities that we believe have the most potential to\nproduce significant near-term value,\u201d said IGM CEO Fred Schwarzer in the\ncompany\u2019s statement.\n\nDec. 5:\n\nReNAgade Therapeutics, which launched in May with $300 in Series A funding, is\nnow laying off 10% of its staff, Fierce Biotech reported Tuesday. The company\nhad about 100 employees at its launch, Fierce reported. While the company has\nnot revealed details about its pipeline, it describes its mission as \u201cto\nunlock the potential for RNA medicines to treat disease anywhere in the body.\u201d\n\nDec. 4:\n\nTravere Therapeutics will reduce its workforce by about 20% in an effort to\nextend its cash runway into 2028, the company announced Monday. The San\nDiego\u2013based biopharma has 462 employees, according to Global Data.\n\nTravere tied the layoffs to the approval process and launch of Filspari\n(sparsentan), which has accelerated approval for IgA nephropathy and which the\ncompany has been testing for focal segmental glomerulosclerosis (FSGS).\n\u201cUnfortunately, there is uncertainty around a regulatory path forward for\nFSGS. While we intend to continue to engage with FDA on a way forward for the\nmore than 40,000 people living with FSGS in the U.S., we must at the same time\nprioritize our operating expenses,\u201d said Eric Dube, president and CEO of\nTravere, in the company\u2019s statement.\n\n## November\n\nNov 30:\n\nPfizer will lay off some staff at its Groton, Connecticut, facility, Fierce\nPharma reported Thursday. A company spokesperson confirmed the move in an\nemail to the outlet but did not specify how many people would be affected.\nAccording to a slide deck posted to Pfizer\u2019s website, the Groton facility\nemploys 2,600 scientists and R&D professionals.\n\nThe Groton cuts are part of a $3.5 billion cost-cutting program Pfizer\nannounced in October, citing falling sales of its COVID-19 products. Since\nthen, the company has reportedly culled staff in Kent, U.K.; Kildare, Ireland;\nMichigan; North Carolina and Colorado.\n\nNov. 30:\n\nStartup Orna Therapeutics has laid off an unspecified number of staff,\nEndpoints News reports. Orna CEO Tom Barnes told Endpoints in an email that\nthe layoff was \u201cdefensive\u201d and affected under one-quarter of the staff. He\nsaid the move would ensure the company can bring its lead product \u201cto a\nmeaningful clinical inflection point without needing to be reliant on capital\nmarkets.\u201d That candidate therapy, ORN-101, consists of circular RNA delivered\nvia lipid nanoparticles to treat tumors.\n\nNov. 29:\n\nGilead is reducing the headcount at its cell therapy business, Kite Pharma, by\nabout 7%, Fierce Biotech reported Wednesday.\n\n\u201cIn some cases, we are also making the decision to reduce the number of roles\nin certain areas of our business that are not aligned to our refreshed\nstrategic priorities and in areas where there may be more efficient ways to\nachieve those priorities, which may impact some team members,\u201d Cindy Perettie,\nexecutive vice president at Kite, told Fierce.\n\nA Gilead spokesperson, however, told the publication that 90 new roles are\nbeing created \u201cthat are better aligned with the organization\u2019s focus,\u201d\nresulting in a net impact of 5%.\n\nNov. 28:\n\nMass.\u2013based Candel Therapeutics is laying off approximately half of its\nworkforce in order to prioritize topline readouts for its lead program,\nCAN-2409, in non-small cell lung, pancreatic and prostate cancers, all\nexpected in 2024. The strategic restructuring plan will also support continued\ndevelopment of CAN-3110, being developed to treat recurrent high-grade glioma,\naccording to the announcement.\n\nCandel currently has 84 employees, per its LinkedIn page.\n\nNov. 28:\n\nIn a company-wide reorganization, Vancouver, BC\u2013based biotech AbCellera\nBiologics is parting with around 10% of its employees. AbCellera announced the\nlayoffs in a regulatory filing Tuesday, where it stated the restructuring is\naimed at increasing its focus on the clinical development of its therapeutic\nantibodies, according to Seeking Alpha.\n\nWith its proprietary antibody discovery and development engine, AbCellera\ntouts the ability to generate a wide range of diverse antibodies, express and\ntest hundreds of antibodies with robust characterization and developability\nassessment, as well as downselect to reveal functional and developable leads.\nAbCellera currently has 582 employees, according to its LinkedIn page.\n\nNov. 28:\n\nNovocure is laying off about 200 people, 13% of its workforce, the company\nannounced Tuesday.\n\nThe biotech revealed in August that its electric field-based treatment had\nfailed to meet the primary endpoint in a Phase III ovarian cancer study.\nAccording to the new announcement, Novocure is now prioritizing readiness to\nlaunch the treatment for metastatic non-small cell lung cancer after\nanticipated approval, as well as for trials on brain metastases and solid\ntumors.\n\nNov. 27:\n\nIn an SEC filing dated Nov. 27, Generation Bio announced it would lay off\naround 40% of its workforce. The move, which will also see the departure of\nthe biotech\u2019s chief medical officer, Douglas Kerr, and chief development\nofficer, Tracy Zimmermann, is expected to extend the company\u2019s cash runway\ninto the second half of 2027.\n\nThe reorganization is intended to allow the gene therapy company to expand its\ncell-targeted lipid nanoparticle (ctLNP) delivery system to targets beyond the\nliver, according to a press release. \u201cWe believe there is a clear path to\ndeveloping our own programs using ctLNP to reach extrahepatic targets and are\nrealigning our investments to support this,\u201d CEO Geoff McDonough said in a\nstatement.\n\nNov. 16:\n\n858 Therapeutics, a San Diego\u2013based biotech developing small-molecule drugs\nfor cancer and other conditions, is laying off an unspecified number of staff\nand closing its New York office, according to a company statement reported by\nFierce Biotech.\n\n858 exited stealth mode two years ago with $60 million in Series A funding. It\nannounced at the time that it had acquired New York\u2013based Gotham Therapeutics,\nand that it planned \u201cto significantly scale up the size of its team to around\n40 people within the next year and a half.\u201d\n\nNov. 14:\n\nBiotech Atreca is laying off 40% of its staff, the company announced Tuesday\nas it reported a Q3 loss of more than $36 million.\n\nAtreca, which focuses on antibody-drug conjugates, underwent previous rounds\nof layoffs in 2022 and earlier this year and said in September that it was\nterminating the lease on its San Carlos, California headquarters in order to\ncut costs. The company reported to the SEC that it had 90 employees as of the\nend of last year.\n\nNov. 14:\n\nPfizer is planning to lay off around 500 of its staffers and terminate its\nPharmaceutical Sciences Small Molecule functions at its facility in Sandwich,\nKent in the U.K., according to several media reports on Tuesday.\n\nThe business scale-back comes amid Pfizer\u2019s sweeping cost-reduction plan\nannounced last month, which will see the company generate $3.5 billion in\nsavings through 2024.\n\nNov. 13:\n\nTheseus Pharmaceuticals announced Monday it is laying off 72% of its\nstaff\u2014about 26 people, Endpoint News reported. Among those let go is President\nof R&D William C. Shakespeare, who will stay on as a consultant until the\nmiddle of next year.\n\nTheseus, which focuses on developing cancer therapies, announced in July that\nit was terminating development of THE-630 after the candidate was found to\nhave dose-limiting toxicities in a Phase I/II trial for gastrointestinal\nstromal tumors. According to Monday\u2019s announcement about the layoffs, \u201cAs part\nof this process, the Company plans to consider a wide range of options with a\nfocus on maximizing shareholder value, including potential sale of assets of\nthe Company, a sale of the Company, a merger or other strategic action.\u201d\n\nNov. 13:\n\nOrbital Therapeutics, a spin-out of Beam Therapeutics that aims to develop\nRNA-based vaccines and therapeutics, is closing its South San Francisco office\nand laying off 16 people, Endpoints News reports.\n\nLaunched in September 2022, Orbital announced this April that it had raised\n$270 million in Series A funding.\n\n\u201cOrbital has made the strategic decision to close our South San Francisco site\nand will scale our operations and expand our team in Cambridge. We are\ngrateful for the dedication and contributions of our impacted colleagues,\u201d the\ncompany said in a statement to Endpoints.\n\nNov. 10:\n\nThermo Fisher will lay off 97 employees in the new year when it closes its\nplants in Auburn, Alabama, according to a WARN notice reported by Endpoints\nNews. The outlet notes that the move follows multiple other layoffs this year\nat Thermo Fisher facilities across the U.S.\n\nNov. 8:\n\nSQZ Biotechnologies is reducing its workforce by approximately 80%, the\ncompany noted Wednesday in its third-quarter earnings release. The cell\ntherapy company has between 51\u2013200 employees, according to its LinkedIn page.\nIn July, Roche announced that it would not expand a years-long collaboration\nwith SQZ around products to target HPV16-positive solid tumors, despite\npositive preliminary Phase I results released earlier this year.\n\nNov. 8:\n\nRegenxbio is reducing its workforce by 15%, the company announced Wednesday.\nRegenxbio said the restructuring will extend its cash runway into 2025 and\nthat it will prioritize its candidate treatments for wet AMD and diabetic\nretinopathy, Duchenne muscular dystrophy and mucopolysaccharidosis type II.\nThe staffing cuts will come \u201cprimarily in rare neurodegenerative disease\ndevelopment, early research, and other general and administrative areas,\u201d\naccording to the announcement. Regenxbio has between 201\u2013500 employees,\naccording to its LinkedIn page.\n\nNov. 7:\n\nLyell Immunopharma will reduce its workforce by approximately 25%, the company\nannounced on Tuesday, with Chief Medical Officer Tina Albertson among those to\npart ways with the company. \u201cWe have restructured our company to prioritize\ninvestment in our clinical-stage programs and core research platforms and have\nstreamlined operations,\u201d said Lyell President and CEO Lynn Seely in the\nannouncement. The company had reported having 274 employees as of the end of\n2022.\n\nEndpoints News noted that Lyell, which specializes in T-cell cancer therapies,\nwas valued at more than $4 billion when it went public in 2021 but is now\nworth about $550 million. A year ago, GSK terminated a deal with the company\nto discover and develop T-cell therapies using Lyell\u2019s technologies.\n\nNov. 7:\n\nArbutus Biopharma is cutting 24% of its staff, the company announced Tuesday\nalong with updates on its candidate therapies to functionally cure chronic\nhepatitis B. Separately, the company announced that its CEO, William Collier,\nwill retire at the end of this year, and that Arbutus Co-founder and Chief\nOperating Officer Michael J. McElhaugh will serve as interim CEO. Arbutus has\nbetween 51\u2013200 employees, according to its LinkedIn profile.\n\nNov. 7:\n\nPyxis Oncology is cutting its headcount by approximately 40%, the company\nannounced on Tuesday. According to the announcement, the layoffs and other\ncost-cutting measures will extend the company\u2019s cash runway to early 2026 as\nit prioritizes two candidates currently in Phase I trials, antibody-drug\nconjugate PYX-201 and immune-oncology therapeutic PYX-106.\n\nAccording to its LinkedIn page, Pyxis currently has between 51\u2013100 employees.\n\nNov. 7:\n\nPfizer is cutting about 100 jobs at its manufacturing plant in Newbridge,\nKildare, Ireland as part of its drive to cut $3.5 billion in costs. The move,\nreported by Fierce Pharma, the Irish Independent, and other outlets, comes as\nthe company says it plans to expand at other sites in Ireland, adding 230\npositions in Dublin and Cork.\n\nNov. 3:\n\nPfizer is laying off around 200 employees at its manufacturing facility in\nKalamazoo, Michigan amid declining sales for its COVID-19 products, according\nto television station Fox 17. Friday\u2019s news comes as the company struggles to\nregain its financial footing from the sharp decline in its COVID-19 business.\nIn an attempt to weather the downturn, Pfizer last month launched a widespread\ncost-cutting initiative designed to generate $3.5 billion in savings through\n2024.\n\nNov. 2:\n\nLocanabio, a company that aimed to develop RNA-editing therapies, will shutter\nby the end of the year, CEO Jim Burns announced on LinkedIn Thursday. \u201cWhile\nwe continue to believe in the potential of our RNA-targeted gene therapy\nplatform to deliver transformative therapies, the decision was made due to the\ntime and capital required to deliver clinical data in the current challenging\nfunding environment,\u201d he wrote. The closure was confirmed by Fierce Biotech.\nLocanabio, based in San Diego, has between 51\u2013200 employees, according to its\nLinkedIn profile.\n\nNov. 2:\n\nKronos Bio will reduce its staff by 19%, the company announced Thursday just\nafter releasing positive preliminary Phase I/II trial data on its antitumor\ncandidate KB-0742. The company also has a therapy, lanraplenib, in development\nfor FLT3-mutated acute myeloid leukemia. \u201cBy streamlining our operations and\nextending our runway, we best position the company to optimally fund our\nKB-0742 clinical studies while continuing to focus on the clinical development\nof lanraplenib, the advancement of our maturing discovery projects, and our\ncollaboration with Genentech,\u201d said Kronos CEO Norbert Bischofberger in the\ncompany\u2019s statement.\n\nAccording to an SEC filing, Kronos had 97 employees at the beginning of this\nyear. The company said its restructuring will extend its cash runway into\n2026.\n\nNov. 2:\n\nSeres Therapeutics will undergo a restructuring that includes reducing its\nworkforce by 41%\u2014approximately 160 positions\u2014the company announced Thursday as\nit touted positive sales data for its microbiome therapeutic, Vowst. \u201cGiven\nthe realities of this challenging financial environment for biopharmaceutical\ncompanies, we believe that concentrating our resources on VOWST offers an\nattractive opportunity for targeted revenue growth, while operating in a more\ncapital efficient manner,\u201d said Seres President and CEO Eric Shaff in the\nstatement.\n\nAccording to the announcement, Seres will prioritize Vowst\u2019s commercial launch\ngoing forward, as well as an ongoing Phase IB study on the microbiome\ntherapeutic candidate SER-155. It will scale back \u201call non-partnered R&D\nprograms and activities.\u201d\n\nNov. 1:\n\nRani Therapeutics will cut its workforce by 25%, the company announced\nWednesday. The company, which is developing orally administered biologics,\nwill halt or pause development of several of its candidate therapies while\nmoving others into Phase I or II trials and expanding its manufacturing\ncapabilities. According to the announcement, the cost-cutting measures will\nextend its cash runway into 2025. Rani has between 51\u2013200 employees, according\nto its LinkedIn profile.\n\nNov. 1:\n\nSangamo Therapeutics is shuttering its Brisbane, California headquarters and\ncutting its U.S. workforce by approximately 162 people\u201440% of its total\nheadcount\u2014the company announced Wednesday. Among those to be let go are Chief\nOperating Officer D. Mark McClung and Chief Scientific Officer Jason Fontenot.\n\nAs part of the restructuring, Sangamo will transition its headquarters to its\nRichmond, California facility and cease investment for now in its\ninvestigative treatment for Fabry disease and in CAR-Treg cell therapy as it\nsearches for partners to continue development of those programs. The company\nwill instead focus on \u201cepigenetic regulation therapies treating neurological\ndiseases and novel AAV capsid delivery technologies,\u201d according to the\nannouncement. Sangamo expects that the restructuring will cut its operating\nexpenses in half, allowing its funds to stretch into the third quarter of\n2024.\n\n## October\n\nOct. 30:\n\nGalapagos and Alfasigma have signed a letter of intent to transfer Galapagos\u2019s\nJyseleca (filgotinib) to Alfasigma. The potential deal, announced by Galapagos\non Monday, would involve the transfer of approximately 400 employees to\nAlfasigma, while 100 others would be laid off. \u201cLooking ahead, the planned\ntransaction is expected to free up significant resources across the\norganization, enabling us to invest more in our R&D growth areas, business\ndevelopment and M&A,\u201d said Galapagos CEO and Chairman Paul Stoffels in the\ncompany\u2019s announcement.\n\nJyseleca is marketed in Europe and Japan for rheumatoid arthritis and\nulcerative colitis. Earlier this year, it failed to meet primary endpoints in\na Phase III trial for Crohn\u2019s disease.\n\nOct. 30:\n\n\u201cPfizer is in the process of closing its Peapack, New Jersey facility that\nwill go in effect in early 2024,\u201d a company spokesperson said in a statement\nto BioSpace. \u201cThe vast majority of colleagues will be re-assigned to Pfizer\u2019s\nNew York headquarters at 66 Hudson Yards with a small portion transitioning to\nthe company\u2019s Parsippany, NJ site. This follows a previously communicated\ndecision in 2021 of plans to sell the Peapack campus.\u201d The spokesperson added\nthat if employees do not want to be reassigned to a different site, their\nemployment will terminate.\n\nThe facility closure coincides with the company\u2019s announcement two weeks ago\nthat it will be cutting $3.5 billion in costs due to disappointing sales of\nthe COVID-19 therapeutic Paxlovid, as well as the Comirnaty vaccine. New\nJersey is far from the only site to feel the effects of the cuts; Fierce\nPharma notes that Pfizer has also announced the closure of two facilities in\nNorth Carolina and reported an unspecified number of layoffs in Colorado.\n\nCorrection (Oct. 30): This story has been updated from its original version to\nreflect the fact that 791 employees are not being laid off in New Jersey, but\nrather are being transferred to new work sites. BioSpace regrets the error.\n\nOct. 26:\n\nElevateBio is cutting 13% of its workforce, a company spokesperson told Fierce\nBiotech Thursday. The Massachusetts-based company is involved in gene editing,\nRNA, cell, vector engineering, protein and induced pluripotent stem cell\ntechnologies; it is not clear how many employees it has. The cuts, to staff\ninvolved in the company\u2019s preclinical work, come despite a $401 million Series\nD financing round that closed in May.\n\n\u201cOur financial position and balance sheet are very strong and we are\nexperiencing robust customer and revenue growth,\u201d the spokesperson told Fierce\nBiotech.\n\nOct. 24:\n\nAmgen is letting go of 350 employees following its $27.8 billion acquisition\nof Horizon Therapeutics, according to several media reports on Tuesday.\n\nThe layoffs will affect Horizon roles that overlap with existing teams at\nAmgen, a company spokesperson told Fierce Pharma. More than 80% of Horizon\u2019s\nstaff will be absorbed into Amgen roles, \u201creflecting the knowledge and\ncapabilities we need to continue serving patients suffering from rare\ndiseases,\u201d a spokesperson for the California-based biopharma said. At the end\nof 2022, Horizon had more than 2,100 employees, according to an SEC filing.\n\nThis is Amgen\u2019s third round of layoffs this year.\n\nOct. 24:\n\nBrainStorm Cell Therapeutics will lay off 30% of its staff, the Israel and New\nYork\u2013based company announced Tuesday. The cost-cutting measure narrows the\ncompany\u2019s focus in the wake of a vote by an FDA advisory committee last month\nagainst approving its amyotrophic lateral sclerosis candidate NurOwn, and\nBrainStorm\u2019s subsequent decision to withdraw its Biologics License Application\nand conduct a Phase IIIb clinical trial on the therapy.\n\nAccording to the company\u2019s announcement, the layoffs are part of \u201ca strategic\nrealignment to enable accelerated development of NurOwn.\u201d Among those let go\nis EVP and Chief Medical Officer Kirk Taylor, whose responsibilities included\nleading launch activities.\n\nAs of June 30, BrainStorm reported that it had 44 employees between the U.S.\nand Israel.\n\nOct. 24:\n\nIdorsia Pharmaceuticals has reduced the workforce at its headquarters in\nSwitzerland by half, the company announced on Tuesday. \u201cApproximately 475\npositions at headquarters in Allschwil, Switzerland, have been made redundant\nthrough a combination of canceling open positions, not replacing people who\nare known to leave (outside the mass dismissal), and up to 300 terminations\nmainly in Research & Development and the associated support functions,\u201d the\nannouncement states.\n\nEndpoints News noted that sales of Idorsia\u2019s insomnia drug, Quviviq, have so\nfar been disappointing. According to the company\u2019s announcement, its cash\nrunway now extends into next year. \u201cOur short-term priority is to further\nextend our cash runway and we are actively reviewing all avenues including\npotential out-license deals with a few balls in the air that we expect to\ncatch in the upcoming months,\u201d Chief Financial Officer Andr\u00e9 C. Muller said in\nthe statement.\n\nOct. 19:\n\nBase-editing company Beam Therapeutics will lay off about 100 employees\u201420% of\nits workforce\u2014it announced on Thursday. The move is part of a restructuring\nplan aimed at funding the company into 2026. Beam\u2019s priorities going forward\nwill include development of its sickle cell disease programs, a base editor to\ntreat alpha-1 antitrypsin deficiency and in vivo editing to treat liver\ndisorders, while its hepatitis B program \u201cwill be paused and designated for\npartnering,\u201d according to the announcement. Reuters reported that shares of\nthe company declined by 2.4% in premarket trading Thursday.\n\nOct. 16:\n\nCell therapy company Nkarta is laying off 18 people, about 10% of its staff,\nit revealed in an SEC filing. The morning after the filing, the company\nannounced that the FDA has cleared its Investigational New Drug application\nfor NKX019, its CAR NK cell therapy candidate for lupus nephritis. The\nannouncement also notes \u201ccost containment measures designed to extend its\nprojected cash runway by one year into 2026.\u201d Nkarta President and CEO Paul\nHastings told Fierce Biotech that the workforce cuts will take place \u201cacross\nthe board,\u201d in accordance with the company\u2019s aim to focus on its later-stage\nprograms.\n\nNkarta\u2019s stock price rose by 112% following its announcement of the FDA\nclearance, Fierce Biotech reported.\n\nOct. 13:\n\nPfizer late Friday launched a sweeping cost-cutting initiative aimed at\ngenerating $3.5 billion in savings through 2024 as the company weathers a\nsteep decline in the sales of its COVID-19 products.\n\nPfizer said the \u201cmulti-year, enterprise-wide cost realignment program\u201d will\ninvolve layoffs, though it is still unclear how many employees will be\naffected. As of August 1, Pfizer employed approximately 83,000 people\nworldwide.\n\nOct. 11:\n\nSana Biotechnology will lay off 29% of its workforce\u2014approximately 120\npeople\u2014as part of a portfolio realignment initiative, the company announced on\nTuesday. Sana will narrow its R&D focus to its ex vivo cell therapy platform\nand move away from an in vivo gene delivery program with an eye toward\nreducing its 2024 operating cash burn to below $200 million. According to the\ncompany, this will allow Sana\u2019s current cash runway to extend further into\n2025 while also providing leeway for investments in clinical capabilities\nacross various indications.\n\nTuesday\u2019s downsizing follows a previous round of layoffs in August, which was\nfirst revealed through a series of LinkedIn posts made by company employees.\nSana later confirmed the downsizing to Endpoints News, but did not disclose\nexactly how many were let go. The biotech also underwent a strategic\nreorganization in November 2022, which included a workforce reduction of\naround 15%.\n\nOct. 9:\n\nBiogen is laying off 113 employees from Reata Pharmaceuticals' Plano, Texas\nsite, according to a Worker Adjustment and Retraining Notification notice. The\nlayoffs, set to take effect in late November, come just months after Biogen\nacquired Reata for $7.3 billion in July 2023.\n\nAt the time, Biogen had just launched a sweeping cost-reduction program that\ninvolved terminating around 1,000 employees in an effort to save $1 billion in\noperating expenses by 2025. Late last month, Biogen completed the acquisition\nof Reata. At the end of 2022, Reata had 321 employees, according to its annual\nreport to the SEC.\n\nOct. 7:\n\nEikon Therapeutics has laid off some of its staff in a bid for efficiency,\nFierce Biotech reported. The outlet obtained an Oct. 5 internal letter to\nstaff from Eikon CEO Roger Perlmutter that reads in part, \u201cAs I discussed at\nthe all-hands meeting last month, our recent success in advancing new programs\nrequires that we become more selective in allocating our resources,\u201d and \u201cthe\nplain fact is that our company, like all companies, must evolve to become more\nefficient.\u201d\n\nEikon, which emerged from stealth in 2021, uses live-cell super-resolution\nmicroscopy and engineering for drug development, but Fierce Biotech calls it\n\u201cfamously tight-lipped about the discovery process.\u201d The company has a Toll-\nlike receptor (TLR) agonist in a Phase I trial to treat advanced solid tumors,\nand last month announced that it has integrated TLR 7 and 8 co-agonists into\nits clinical development program and that it plans to begin a Phase I trial on\nits PARP1 inhibitor\u2014another experimental cancer drug developed with Impact\nTherapeutics\u2014this year.\n\nOct. 5:\n\nNorth Carolina-based gene therapy biotech Atsena Therapeutics recently laid\noff an undisclosed number of employees to conserve cash, multiple sources\nreported Thursday. Atsena has also raised about $24.5 million of a targeted\n$32 million in an insider-led Series B round, the company told Endpoints News.\nAtsena is expecting data from a Phase I/II trial of its lead program,\nATSN-101, targeting the retinal disease Leber congenital amaurosis (LCA) by\nthe end of this year, Endpoints reported. It kicked off another Phase I/II\ntrial of a second gene therapy, ATSN-201, for RS1-associated X-linked\nretinoschisis (XLRS)\u2014a rare congenital retinal disease\u2014in August.\n\nOct. 5:\n\nuniQure is laying off 114 people, about 20% of its total workforce, the gene\ntherapy company announced Thursday. The company \u201cwill discontinue more than\nhalf of its research and technology projects, including AMT-210 for the\ntreatment of Parkinson\u2019s disease and multiple undisclosed programs,\u201d according\nto the announcement, while focusing on AAV capsid development and treatments\nin development for ALS and Alzheimer\u2019s disease. uniQure will also continue\nseveral clinical-stage programs, including an investigational treatment for\nHuntington\u2019s currently in Phase I/II trials.\n\nThe company said the moves will save $180 million, extending its cash runway\ninto 2027. As part of the restructuring, Chief Scientific Officer Ricardo\nDolmetsch is leaving the company, and uniQure executive Richard Porter will\nassume a new role as chief business and scientific officer.\n\nOct. 3:\n\nKezar Life Sciences is laying off 41% of its workforce and its CEO and chief\nmedical officer will step down as part of a restructuring, the company\nannounced Tuesday. Kezar has paused all of its research and drug discovery\nefforts, according to the announcement, as it focuses on shoring up enough\nfunds for its Phase IIb clinical trial of the experimental drug zetomipzomib\nin lupus nephritis. The company anticipates having top-line data from that\ntrial in mid-2026, with data from its Phase I trial of a drug for solid tumors\nand a Phase IIa trial of zetomipzomib in autoimmune hepatitis expected in the\nmeantime.\n\nCompany co-founder and member of the board Christopher Kirk will replace\nfellow co-founder John Fowler as CEO, and Zung To, the current senior vice\npresident for clinical development operations, will step into the role of\nchief medical officer.\n\nOct 2:\n\nSyros Pharmaceuticals is laying off 35% of its workforce, and its CEO and\nchief science officer are also departing, the company announced Monday. Syros\nsaid it is ending a Phase I trial of a potential treatment for a type of\nleukemia, as well as earlier-stage work on that drug, to focus on\ntamibarotene, another blood cancer treatment that is currently in Phase II and\nIII trials.\n\nCEO Nancy Simonian, who has led the company since 2012, will retire in\nDecember, the company said, but she will remain on the board of directors.\nReplacing her will be Conley Chee, currently Syros\u2019 chief commercial officer\nand chief business officer. Chief Scientific Officer Eric Olson will depart\nthe company later this month. Syros had 117 employees as of the end of 2022,\naccording to its most recent SEC filing.\n\n## September\n\nSept 28:\n\nPTC Therapeutics announced Thursday it is laying off a further 25% of its\nworkforce. The move continues a restructuring the company began in May, when\nPTC laid off 8% of its employees and announced that it would discontinue\nseveral early-stage gene therapy development programs. Thursday\u2019s announcement\nnotes that the company \u201ccontinues to focus its resources on its\ndifferentiated, high potential R&D programs and on support of the robust\nglobal commercial infrastructure.\u201d It adds that PTC will submit a re-\nexamination request regarding a recent decision by the EU\u2019s Committee for\nMedicinal Products for Human Use (CHMP) recommending against renewal of\nconditional authorization for Translarna for Duchenne muscular dystrophy.\n\nIn its most recent annual filing, at the end of 2022, PTC reported that it had\n1,410 employees.\n\nSept 26:\n\nDenmark\u2013based biotech Galecto is searching for strategic alternatives after\nits lead lung disease asset failed the primary efficacy endpoint in a mid-\nstage trial in August. On Tuesday, the company announced it would lay off\napproximately 70% of its workforce\u2014which equates to about 30 people. As part\nof its business evaluation, Galecto is also considering a number of\nopportunities, including an acquisition, merger, business combination or\ndivestiture of assets, technologies or capabilities.\n\nFollowing the Phase IIb trial failure, Galecto announced it would discontinue\ndevelopment of GB0139, which was being developed for idiopathic pulmonary\nfibrosis (IPF). The company also stated it was re-evaluating its options and\nresource allocation plans \u201cwith the goal of extending our cash runway into\n2025.\u201d\n\nSept 26:\n\nIn a \u201cworkforce realignment,\u201d AM-Pharma announced Tuesday it has completed a\nworkforce reduction but did not provide specific numbers. The\nNetherlands\u2013based biopharma is also switching it up at the top, with Juliane\nBernholz\u2014currently chief operating officer\u2014succeeding Erik van den Berg as\nCEO.\n\nThese moves come nearly a year after AM-Pharma halted a pivotal Phase III\ntrial of its recombinant alkaline phosphatase, ilofotase alfa, in sepsis-\nassociated acute kidney injury after it failed the primary endpoint of rate of\nall-cause deaths at 28 days.\n\nSept 26:\n\nFrench biopharma Poxel is seeking new financing to initiate Phase II proof-of-\nconcept studies for its adrenoleukodystrophy (ALD) assets, PXL770 and PXL065,\nand to \u201cexecute its rare diseases strategy.\u201d\n\nIn the same announcement, the company disclosed that its headcount now stands\nat 15 employees, which compares to 37 at the end of December 2022 and 16 at\nthe end of August, according to reporting by Endpoints News. Poxel is also\ntaking a $17.6 million impairment, which \u201caims to best reflect the current\nvalue of PXL065\u201d and takes into account the need to \u201cobtain additional\nfinancing to pursue its development plan in NASH [non-alcoholic\nsteatohepatitis] or ALD,\u201d along with its current market capitalization and the\nmacroeconomic context in which the company operates.\n\nSept 22:\n\nIt took more than four months, but ImmunityBio is laying off 48 staffers after\nfailing to win approval in May for its bladder cancer therapy. The layoffs,\nwhich were revealed in a Sept. 19 California WARN notice, affect employees at\nthe company\u2019s El Segundo, California site, as well as remote workers who\nreport to that site, Fierce Biotech reported on Friday.\n\nIn May, the company, headed by Patrick Soon-Shiong, had received a Complete\nResponse Letter for the bladder cancer hopeful in which the FDA cited\ndeficiencies with its third-party contract manufacturer. It\u2019s also the\nbiopharma\u2019s second round of layoffs in less than a year. In October 2022,\nImmunityBio parted with 30 employees due to \u201ceconomic reasons\u201d at a New York\nfacility that was expected to expand the company\u2019s manufacturing footprint.\n\nOn Sept. 11, the company announced it had taken on a $200 million convertible\ndebt note from Nant Entities, an affiliate associated with Soon-Shiong, its\nfounder, executive chair and global chief scientific and medical officer.\n\nSept 19:\n\nNightHawk Biosciences is flying in a different direction as it turfs its R&D\nbusiness in favor of its contract development and manufacturing organization,\nScorpius Biomanufacturing. The plan will see NightHawk part with 13 employees\nin the R&D business, the equivalent of 14% of its workforce. The company\nbelieves the pivot \u201crepresent(s) its best opportunity for success\u201d and said in\nan SEC filing that the layoffs, which will take place immediately, are\nexpected to save $1.8 million in annual compensation.\n\nScorpius\u2014a Texas-based CDMO specializing in mammalian, microbial and cell- and\ngene-based therapies\u2014brought in $700,000 during the second quarter of 2023,\nFierce Biotech reported, while the R&D business cost NightHawk $5.7 million in\nthe same timeframe, according to the company\u2019s Q2 business update.\n\nSept 19:\n\nAfter a fresh start as Fresh Tracks Therapeutics a year ago, the company\nformerly known as Brickell Biotech will shut its doors for good. Fresh Tracks\nwill discontinue all of its clinical and preclinical development programs and\nlay off \u201cmost employees\u201d by early October, according to a statement issued\nTuesday. The Colorado\u2013based company had undertaken an \u201cextensive\u201d search for\nstrategic alternatives, following which the Board of Directors decided to\nliquidate and dissolve the outfit. Certain employees, consultants and advisors\nwill remain to oversee the wind-down of the company.\n\nFresh Tracks officially changed its name in September 2022 to reflect its\nstrategic shift toward developing groundbreaking autoimmune and inflammatory\ndisease therapies.\n\nSept 18:\n\nHistogen is history. The San Diego\u2013based biotech, which is focused on treating\ninfectious diseases, announced that \u201cafter extensive consideration of\npotential strategic alternatives,\u201d it will close its doors. Accordingly,\nHistogen is discontinuing all clinical development programs and will let most\nemployees go by the end of September.\n\n\u201cThe Board of Directors and management devoted substantial time and effort in\nidentifying and pursuing various opportunities, but we were unable to complete\na transaction that would allow us the potential to enhance stockholder value,\u201d\nSteven J. Mento, president and CEO of Histogen, said in a statement.\n\nSept 18:\n\nBay area-based Kinnate Biopharma is undertaking a \u201creprioritization and\nworkforce restructuring\u201d plan that will reduce by 70% its current employees.\nThe review, which considers the company\u2019s cash runway, near-term pipeline\nvalue creation prospects, the evolving regulatory landscape for targeted\ntherapies and other factors, will see Kinnate left with 28 full-time staff\nmembers, according to a press release issued Monday. The layoffs include all\nemployees at Kinnate\u2019s Chinese subsidiary, Kinnjiu Biopharma.\n\nThe cancer-focused company will focus its attention on KIN-8741, an\nexarafenib/binimetinib combination being developed for a range of solid tumors\nwhere c-MET is overexpressed, and its brain-penetrant CDK4 selective program,\nfor which it plans to nominate a candidate in the fourth quarter of 2023.\nMeanwhile, it has paused development of KIN-7136, a brain-penetrant MEK\ninhibitor for MAPK pathway-driven solid tumors.\n\nSept 15:\n\nNearly two months after Lyndra Therapeutics replaced CEO Patricia Hurter with\nExecutive President and Chief Operations Officer Jessica Ballinger, the\nWatertown, Mass.\u2013based company is laying off nearly a quarter of its staff,\nEndpoints News reported. The layoffs are the result of the company\u2019s decision\nto outsource commercial manufacturing and partner on both the development and\ncommercialization of \u201call future products,\u201d a spokesperson told Endpoints on\nFriday. Lyndra, which in 2019 teamed up with Gilead to develop and market\nultra-long-acting oral HIV therapies, is expecting a top-line data readout\nfrom a pivotal trial of its long-lasting schizophrenia drug in \u201cthe next\nweeks,\u201d the spokesperson said, \u201cand we feel these changes will set us up to\nsuccessfully navigate the regulatory pathway ahead and ultimately bring oral\nweekly medications to patients.\u201d\n\nSept 12:\n\nA \u201cconvergence\u201d of factors led to the announcement that 2seventy bio will lay\noff approximately 40% of its staff in a sweeping reorganization that includes\nthe departure of CEO Nick Leschly. On an investor call Tuesday, Leschly cited\nthe \u201cdifficult and unpredictable macro environment\u201d as the rationale behind\nthe decision but added that delays experienced by the company\u2019s later-stage\nprograms and \u201ccomplicated Abecma commercial dynamic\u201d were also factors. Abcema\nis 2seventy\u2019s approved treatment for relapsed or refractory multiple myeloma.\nThe company will also advance fewer pipeline programs, according to the\nannouncement.\n\nThe workforce reduction\u2014which represents 176 roles\u2014is expected to generate an\nannualized cost savings of at least $65 million.\n\nSept 11:\n\nIsrael\u2013based Enlivex Therapeutics is doubling down on its inflammatory and\nautoimmune indications\u2014and tagging its oncology programs for either external\ncollaborations or out-licensing\u2014resulting in a 50% workforce reduction. In a\npress release issued Monday, Enlivex stated it expects the cuts and\nreclassification of the oncology indications to extend its cash runway through\nthe end of 2025. As part of this push, the company has initiated a new program\nin osteoarthritis after preclinical evidence from its most advanced candidate,\nAllocetra, showed promise in this indication. Enlivex\u2019s most advanced program\nis in organ failure associated with sepsis.\n\nSept 6:\n\nCSL Vifor will be 85 employees lighter at its California location as of Oct.\n25. CSL Vifor\u2014which was established following the completion of CSL\u2019s $11.7B\nacquisition of Vifor Pharma in August 2022\u2014revealed the cuts in a California\nWARN notice. The addition brought Vifor\u2019s iron deficiency and kidney disease\nportfolios under CSL\u2019s extensive umbrella.\n\nThe layoffs are the result of a strategic review that found changes to the\nU.S. commercial business were required \"in light of [CSL Vifor's] current\nportfolio of marketed products and near to mid-term prospects to deliver cost,\nrevenue and growth synergies,\u201d a company spokesperson told Fierce Pharma in an\nemail.\n\nSept 5:\n\nThe hits just keep coming for Infinity Pharmaceuticals, which in July laid off\napproximately 78% of its workforce\u2014or 21 employees\u2014after the company\u2019s planned\nmerger with MEI Pharma broke down. On Friday, Infinity\u2019s depleted board\u2014the\ncompany reduced its board members from eight to five in July\u2014terminated CEO\nAdelene Perkins and Chief Medical Officer Robert Ilaria Jr. as part of the\nongoing restructuring plan, Seeking Alpha reported. Another three employees\nwere also let go. As of Sept. 5, Infinity\u2019s website lists Seth Tasker as CEO\nand the lone member of the leadership team.\n\n## August\n\nAug 31:\n\nThe Labor Day long weekend began on a sour note for more than half of the\nemployees at Maryland\u2013based NexImmune. The biotech, which is developing\nimmunotherapies for cancer, autoimmune and infectious diseases, announced it\nwill lay off approximately 53% of its staff, turning a workforce of 47 full-\ntime employees into one of just 22 as of September 5. The move was designed to\nreduce costs and extend the company\u2019s cash, according to the announcement. The\ndepartures include chief financial officer John Trainer, whose final day was\nlisted as September 2.\n\n\u201cThe workforce reduction protects our core capabilities to advance novel\ntherapeutic candidates and our multiplex validation of functional antigen-\nspecific T cell responses while giving us additional flexibility to manage our\nbusiness,\u201d CEO Kristi Jones said in the announcement.\n\nAug 31:\n\nOn the cusp of receiving its first clinical data\u2014for SC291, a CD19-targeted\nallogeneic CAR T cell therapy\u2014Sana Biotechnology is laying off an undisclosed\nnumber of its staff.\n\nThe revelation is based on about half a dozen LinkedIn posts recently made by\nSana employees, according to Endpoints News, which reported the layoffs on\nThursday.\n\n\u201cDue to company restructuring and downsizing, my role, and the role of many of\nmy incredible colleagues, have been eliminated,\u201d Cole Delyea, a senior\nresearch associate, posted on the business networking platform. In an email to\nEndpoints, a Sana spokesperson confirmed that it had found \u201coperating\nefficiencies within a single area of research.\u201d\n\nThe FDA cleared Sana\u2019s IND application for SC291 in January.\n\nAug 31:\n\nAfter winning approval for Zurzuvae (zuranolone) in postpartum depression\n(PPD) but failing to secure the larger prize of a major depression nod, Sage\nTherapeutics CEO Barry Greene said the company was evaluating a workforce\nreorganization. Thursday, that came to fruition as the Cambridge, Mass.\u2013based\nbiotech announced it would lay off approximately 40% of its staff. The move is\nintended to \u201cright-size\u201d the organization and enable commercial hires\nnecessary for a fourth-quarter launch of Zurzuvae in PPD, according to the\npress release. Along with the workforce cuts, Sage announced that CSO Al\nRobichaud and Jim Doherty, chief development officer, will be departing the\ncompany.\n\nAug 29:\n\nApellis Pharmaceuticals will let go 225 employees, or 25% of its staff, the\ncompany announced on Monday. Coming off stock drops following safety concerns\nover its recently approved eye injection Syfovre--which turned out to be\nrelated to the needle used to deliver the medicine, not the drug itself--\nApellis stated that it's looking to save money in the near-term to achieve\n\"long-term success.\" The company is also facing competition from Astellas,\nwhose eye therapy Izervay was approved earlier this month.\n\nAug 24:\n\nPfizer is laying off 69 employees at a plant in Lake Forest, IL, according to\na July WARN notice from the state, though some employees may be able to\ntransition to other roles in the company, a Pfizer spokesperson told Becker's\nHospital Review. \"We have made the very difficult decision to discontinue some\nresearch projects to focus on programs where our innovation and investments\nmay be best positioned to deliver high-impact breakthrough medicines and\nvaccines.\"\n\nAug 24:\n\nAgenus is cutting 25% of its workforce, according to a company press release\nissued on Wednesday. The immuno-oncology firm is refocusing its resources on\nits flagship program botensilimab/balstilimab (BOT/BAL), a CTLA-4/PD-1 combo\ntreatment being developed for solid tumors, including colorectal cancer and\nmelanoma, while halting all other preclinical and clinical programs for the\ntime being. \"Now is the pivotal moment to concentrate our efforts on the\nBOT/BAL program,\" Chairman and CEO Garo Armen said in the statement. \"The\nobserved clinical benefit in solid tumors underscores the program\u2019s game-\nchanging potential, and our rapid progress towards a first filing in 2024\nhighlights the necessity for prioritization in every aspect of our\noperations.\"\n\nAug 23:\n\nNovartis will cut 103 jobs this fall, according to a state WARN notice. The\nlayoffs will again affect the company's East Hanover, NJ, headquarters and\nfocus on clinical operations, Fierce Pharma reported. The move comes with a\ncampus redesign and is part of a new approach to \u201cenable faster trial\nrecruitment and enhanced trial delivery,\u201d a Novartis spokesperson told the\npublication. This is the company's first significant round of layoffs since it\nannounced late last year that its restructuring initiative would eliminate 285\njobs in the early part of 2023.\n\nAug 22\n\nLava Therapeutics will lay off 36% of its employees, the company announced\nwith its second-quarter financial update today. The cuts come along with\nefforts to reprioritize Lava's portfolio following the company's June decision\nto discontinue development of LAVA-051, a gammabody intended to target\nCD1d-expressing tumors, including multiple myeloma, chronic lymphocytic\nleukemia and acute myeloid leukemia. At the end of last year, Lava had 69\nfull-time employees, Endpoints News reported.\n\nAug 22:\n\nAravive is laying off 70% of its staff, which numbered 23 people at the end of\nlast year, according to an SEC filing. The terminations, which include Chief\nOperating Officer Scott Dove, come as the company shutters clinical\ndevelopment of the decoy protein batiraxcept, which recently failed to improve\nprogression-free survival in a Phase III trial of platinum-resistant ovarian\ncancer. In addition to its ovarian cancer program, the company was testing\nbatiraxcept in Phase Ib/II trials of clear cell renal cell carcinoma and\npancreatic cancer, but following the Phase III flop, the company has decided\nit needs to conserve cash, the filing stated.\n\nAug 18:\n\nBlueRock Therapeutics is laying off about 50 people, or about 12% of its\nemployees, Endpoints News reported. The cuts will affect sites in New York,\nToronto and Cambridge, MA. BlueRock is the cell therapy arm of Bayer, which\nbought the biotech in 2019. In June of this year, BlueRock announced positive\nPhase I data for its stem cell therapy bemdaneprocel, being developed for the\ntreatment of Parkinson\u2019s disease.\n\nAug 15:\n\nStarting in October, Thermo Fisher Scientific is letting go 205 employees from\ntwo sites in Alachua, Florida, according to a recent WARN notice. According to\nFierce Pharma, the 95,000-square-foot Alachua facility oversees analytics and\nprocesses for viral vector systems and conducts quality control testing and\nmanufacturing for cell and gene therapies in clinical development but is no\nlonger listed on Thermo's website. This marks the company's sixth round of\nlayoffs this year, having cut nearly 600 employees in the San Diego area and\nan additional 113 in New Jersey.\n\nAug 15:\n\nAlaunos Therapeutics will lay off 60% of employees as it runs out of cash to\ncontinue operations, the company announced with its second-quarter financial\nresults. The move comes hand in hand with a strategic shift that involves\nmoving away from its TCR-T Library Phase 1/2 trial and focusing on its hunTR\nTCR discovery platform while exploring partnering opportunities. It's unclear\nhow many people will be affected by the layoffs, but according to an SEC\nfiling the company had 34 full-time employees as of February.\n\nAug 14:\n\nBioXcel Therapeutics is cutting its workforce by more than half, dropping from\nabout 190 employees to 80, the company announced with its second-quarter\nearnings on Monday. The move came as the New Haven, Conn.\u2013based, AI-focused\nbiopharma company aims to reduce operating expenses by more than 50%,\naccording to the press release. Additional strategic shifts include halting\ncertain programs altogether and focusing on the development of BXCL501 for at-\nhome treatment of agitation in schizophrenia, bipolar disorders, and mild to\nmoderate dementia due to probable Alzheimer\u2019s disease.\n\nAug 14:\n\nBristol Myers Squibb will lay off 108 employees later this year, according to\na New Jersey WARN report. The news comes shortly after the company announced\nits second-quarter earnings, which showed notably reduced sales of its\nchemotherapy Revlimid and lower overall revenue projections for 2023. It's the\nsecond round of layoffs to hit BMS this year, with 48 staff members at its\nPrinceton, New Jersey, facility losing their jobs in May.\n\nAug 10:\n\nSan Carlos, Calif.\u2013based biotech Atreca is reorganizing its pipeline,\nsuspending development of its lead candidate ATRC-101, a solid tumor\nmonoclonal antibody, and cutting its workforce by 40%. The cuts will cost the\ncompany approximately $1.6 million, mostly in severance payments, according to\nan 8K filing dated Aug. 10. The remaining Atreca staff will focus their\nattention on the company\u2019s preclinical antibody-drug conjugate candidates,\nwith the company particularly highlighting APN-497444, being developed for\ngastrointestinal cancers.\n\nAug 9:\n\nImmediately following the FDA\u2019s rejection of avasopasem manganese\n(avasopasem)\u2014intended to treat severe oral mucositis (SOM), or mouth sores,\nresulting from radiotherapy in patients with head and neck cancer\u2014Galera\nTherapeutics announced it would lay off approximately 70% of its workforce.\nThe move is one action the Malvern, Penn\u2013based company is taking to extend its\ncash runway as it winds down commercial readiness efforts, according to a\npress release announcing the Complete Response Letter. The reductions will be\nfelt across several departments.\n\n\u201cWe are grateful for the many contributions our talented team has made over\nthe years and their commitment to avasopasem,\u201d Galera President and CEO Mel\nSorensen said in a prepared statement.\n\nAug 9:\n\nINOVIO Pharmaceuticals is abandoning development of its cervical lesion\nprogram, VGX-3100, along with 58 of its employees. The layoffs, which equate\nto 30% of INOVIO\u2019s overall workforce, are the third staff reductions in the\nspan of just over a year for the Pennsylvania-based company. In July 2022,\nINOVIO parted with 18% of its staff after encountering challenges in efforts\nto develop a COVID-19 vaccine. Then in January, looking for further cost\nsavings, the company laid off an additional 11% of its team.\n\nAug 8:\n\nHouston\u2013based biotech Salarius Pharmaceuticals is reducing its small team by\nmore than half as it explores strategic alternatives and takes measures to\nextend its resources. These measures may include \u201cacquisition, merger, reverse\nmerger, divestiture of assets, licensing or other strategic transactions,\u201d\naccording to the press release. Salarius President and CEO David Arthur said\nthe decision to limit further drug development was \u201cexceptionally difficult\u201d\nin light of recent clinical wins that include FDA clearance of a Phase I trial\nfor targeted protein degrader SP-3164 in non-Hodgkin lymphoma. The company\u2019s\nremaining employees will focus on \u201climited drug development activities.\u201d\n\nAug 8:\n\nIn a shift away from contract manufacturing, Emergent BioSolutions will part\nways with approximately 400 employees. The changes, which come as Emergent\nfocuses its resources on its core businesses\u2014medical countermeasures and\nNarcan\u2014will also see the reduction of operations at the company\u2019s facilities\nin Baltimore, MD, and Canton, MA. Emergent\u2019s contract manufacturing business\ntook a hit two years ago when cross-contamination ruined millions of doses of\nJohnson & Johnson\u2019s COVID-19 vaccine. The 400 individuals laid off Tuesday\njoin 132 of their colleagues who lost their jobs in another \u201corganizational\nrestructuring\u201d in January.\n\nAug 8:\n\nSan Francisco\u2013based clinical trials company Curebase has laid off an\nundisclosed number of employees as it sunsets its full-service clinical\noperations business, CEO Tom Lemberg announced in a LinkedIn post. Lemberg put\nthe decision down to the current state of the industry, saying, \u201cWe regret the\nturbulence our industry is experiencing, including staffing reductions at\nCurebase and many of our peer startups trying to make an impact in this\nspace.\u201d\n\nAug 3:\n\nCelsius Therapeutics announced the launch of its first clinical trial for its\nlead asset CEL383, an anti-TREM1 antibody intended to treat inflammatory bowel\ndisease\u2014but it appears the Mass.-based company hobbled to the starting gate,\nrecently laying off around two-thirds of its employees, CEO Tariq Kassum told\nSTAT News. Celsius has also halted nearly all of its early-stage research work\nin order to launch the Phase I trial, Kassum told STAT.\n\n\u201cI do think that you\u2019re seeing a lot of other companies doing what we are,\nwhich is, as painful as it is, to focus on the nearest-term value drivers, the\nthings that can get to patients the quickest, and make the painful decisions\nthat allow you to live to fight another day,\u201d he said.\n\nAug 2:\n\nIn an effort to focus on its late-stage core programs, Karyopharm Therapeutics\nwill reduce its workforce by around 20%, the Mass.-based company announced in\nits second-quarter financial report. The move will affect both full-time\nemployees and contractors, Karyopharm stated. An SEC filing puts the company\u2019s\ntotal workforce at 385 as of Feb. 10, meaning the cuts could affect around 80\npeople. With the move, Karyopharm expects to have cash runway into late 2025.\n\nAug 2:\n\nIntergalactic Therapeutics, launched in 2020 by Apple Tree Partners and former\nPfizer and Biogen exec Michael Ehlers, is parting ways with all of its\nemployees and will \u201cexplore strategic options\u201d, according to Heather Shea, a\ncompany spokesperson who confirmed the news to the Boston Business Journal.\n\nIn a LinkedIn post, Joseph Graskemper, the company\u2019s head of external\nmanufacturing and supply chain, indicated that economic reasons were at play\nin the decision. \u201cThe current economic environment has led to challenging\ntimes for companies to raise capital,\u201d Graskemper wrote. \u201cUnfortunately,\nIntergalactic Therapeutics was not immune to these challenges and all\nemployees have been laid off, myself included.\u201d\n\nIntergalactic was developing non-viral gene therapies.\n\nAug 2:\n\nCharles River Laboratories will shutter its discovery site in South San\nFrancisco, a company representative confirmed in an email to BioSpace on\nAugust 1. The facility, located at 225 Gateway Blvd., employed 55 people,\nranging from entry- to senior-level scientific and technical staff. The\ndecision was made based on a determination that the pharmacokinetic and\npharmacology services provided by the site \u201care not currently a strategic fit\nto support future growth,\u201d the representative said, adding that the company\u2019s\nantibody discovery and CRADL locations in South San Francisco are not\naffected.\n\nAug 2:\n\nAnother plant is shutting its doors, this one belonging to SterRx, a New\nYork\u2013based company that makes therapeutic products, including calcium-channel\nblocking agents, sedatives and vasopressors. The move, announced in a WARN\nnotice dated July 26, will affect 161 employees. The decision, which involves\ntwo sites, was made due to economic reasons, according to the WARN notice. The\nfirst layoffs are expected to happen on Oct. 24, the same date listed for the\nclosing of the facility.\n\n## July\n\nJuly 28:\n\nIn a pipeline reprioritization, Ribon Therapeutics has made \u201ccuts across the\norganization,\u201d Chief Business Officer Gary Sutton told Endpoints News, which\nbroke the news of the layoffs. The Cambridge, MA\u2013based biotech has also ended\nits preclinical and platform work to prioritize development of two clinical\nprograms: RBN-2397, an oral PARP7 inhibitor being tested in a Phase I trial of\npatients with solid tumors, and RBN-3143, an inhibitor of PARP14 currently in\nPhase I for moderate to severe atopic dermatitis. Sutton did not disclose the\nnumber of employees affected, Endpoints reported.\n\nJuly 28:\n\nOn the heels of what it called \u201cencouraging\u201d data from a Phase I study\nevaluating HMI-103\u2014an investigational gene editing candidate\u2014in\nphenylketonuria (PKU), Homology Medicines is laying off nearly its entire\nworkforce as it evaluates strategic options. Homology stated that despite the\npositive data for HM1-103, it would be shuttering its programs and reducing\nits workforce by 87%. In a press release, the company said the decision is due\nto \u201cthe current financing environment and Homology\u2019s anticipated clinical\ndevelopment timelines.\u201d\n\nJuly 27:\n\nMersana Therapeutics will lay off around half of its workforce after the Phase\nIII failure of its lead antibody-drug conjugate (ADC), upifitamab rilsodotin\n(UpRi), in ovarian cancer. Mersana announced Thursday that UpRi failed to meet\nthe primary endpoint of investigator-assessed objective response rate in the\nUPLIFT trial, which was studying the therapeutic in patients with\nNaPi2b-positive ovarian cancer. This spells the end of the UpRi program, which\nalso includes the UP-NEXT and UPGRADE-A clinical trials, which were both\nplaced on partial clinical holds by the FDA in June, as Mersana said it would\nwind down development activities related to the ADC.\n\nJuly 25:\n\nAfter the breakdown of its planned merger with MEI Pharma, Infinity\nPharmaceuticals is laying off approximately 78% of its current workforce in\nwhat the company is calling a value preservation and maximization plan. In\naddition to parting with 21 employees, Infinity will reduce its board from\neight members to five and the remaining members will finish out their term\nuncompensated. On Monday, Infinity announced it had terminated the planned\nmerger after MEI failed to obtain stockholder approval for the deal.\n\nJuly 25:\n\nIn a sweeping move, Biogen will cut 11% of its workforce\u2014amounting to\napproximately 1,000 jobs\u2014as it gears up for the launch of Alzheimer\u2019s drug\nLeqembi, which gained full approval earlier this month. The layoffs are part\nof a larger cost-cutting and reorganization effort that began in 2022 on the\nheels of a disappointing rollout for the company\u2019s other Alzheimer\u2019s drug,\nAduhelm. The larger plan, dubbed \u201cFit for Growth\u201d is expected to save\napproximately $1 billion in gross operating expenses by 2025, Biogen stated in\nits Q2 earnings report.\n\nJuly 24:\n\nThe hits keep coming for Heron Therapeutics. Just over a year ago, Heron cut\n34% of its workforce in what it called a \u201ccorporate restructuring and cost\nreduction plan.\u201d Monday, the San Diego\u2013based biotech was back with another\ncorporate restructuring that will cost 25% of its employees their jobs. The\noverall cost reduction plan\u2014which also includes streamlining operational\nexpenditures, including reductions in R&D\u2014is expected to save $75 million in\ncash through 2025.\n\nJuly 21:\n\nIllumina is laying off 151 workers in California, according to WARN notices\nfiled with the state. The cuts include 79 workers in San Diego, 71 in Foster\nCity and one in Hayward. The layoffs are part of an initiative to save $100\nmillion by the end of the year.\n\nEliem Therapeutics announced it is dropping its one remaining program and\nexploring strategic alternatives, including a potential sale of its business.\nThis comes five months after the biotech laid off 55% of its staff and dropped\nits Phase II depression candidate.\n\nIdorsia announced plans to lay off up to 500 workers in an attempt to cut\nspending in half at its headquarters in Allschwil, Switzerland by early 2024.\nThe company has decided to stop its R&D efforts while it waits for Quviviq,\nits insomnia treatment, to bring in more cash.\n\nCodexis announced it will no longer develop its own therapeutics and will\nfocus on selling its existing technology and services. This shift will result\nin cutting 25% of its workforce and closing its facility in San Carlos, CA.\n\nPassage Bio announced plans to cut 26% of its staff, including its chief\nfinancial officer and chief technical officer, according to an SEC filing. The\ncuts will be focused primarily on its chemistry, manufacturing and controls\n(CMC) division.\n\nJuly 19:\n\nAmgen is laying off four members of staff from its San Carlos, CA facility\neffective Sept. 1, according to a WARN notice. This is the company's third\nround of layoffs since Jan. 1. The first, announced in January, included 300\nworkers, and the second, announced in March, included 450.\n\nFibroGen is cutting 104 workers in the U.S., or approximately 32% of its\nworkforce, according to an SEC filing published Wednesday. This followed news\nin June that the company's idiopathic pulmonary fibrosis candidate,\npamrevlumab, failed to meet its primary endpoint in a Phase III trial.\n\nAmarin Corporation PLC announced it plans to lay off all workers in U.S. sales\npositions and eliminate 30% of non-sales roles as part of a restructuring\ninitiative following the appointment of a new CEO. The company stated it will\nkeep a small team on staff to continue developing its lead candidate, Vascepa.\n\nPieris Pharmaceuticals announced Tuesday that it is undergoing a restructuring\ninitiative and laying off 70% of its workforce after AstraZeneca pulled out of\nits partnership and licensing deal for its asthma treatment, elarekibep.\n\nJuly 12:\n\nCapsida Biotherapeutics is laying off staff, according to multiple outlets,\nbut the company has not confirmed how many workers would be affected. Fierce\nBiotech reported the layoffs could include up to 25% of the team, citing \"a\nsource familiar with the decision.\"\n\nSagent Pharmaceuticals is laying off 81 workers at its Raleigh, NC campus,\naccording to a WARN notice filed with the state of North Carolina. The layoffs\nwill take place on Aug. 11. Sagent acquired the facility in 2019, and at the\ntime, it housed about 120 workers.\n\nAVROBIO announced it is stopping the development of three gene therapies,\ncutting its workforce by about half and is on the lookout for a buyer for the\nrest of its assets, according to an SEC filing.\n\nTheratechnologies announced it is cutting an unspecified number of workers in\nits R&D division in an effort to save cash, according to its Q2 financial\nreport. Sales for both Trogarzo, a treatment for HIV infection and Egrifta, a\ntreatment for fat gain due to HIV infection, were down 9% in Q2, and the\ncompany expects to save an extra $5.5 million annually by cutting down its R&D\nspending.\n\nBAKX Therapeutics announced that as of July 1, it has shut the doors to its\noffices and labs, dissolved the company and laid off almost all of its staff.\nSeveral key members of the company, based in Watertown, MA, will stay put\nuntil Aug. 1.\n\nJuly 7:\n\nTrueBinding, a California biotech developing therapies for Alzheimer's, has\nrecently undergone two rounds of layoffs, according to Endpoints News, which\ncited LinkedIn posts as its source. The company did not respond to the\noutlet's request for comment, but according to PitchBook, TrueBinding now has\n27% fewer staff than it did in July 2022.\n\nGalvanize Therapeutics conducted a round of layoffs last week, according to\nmultiple outlets, just 10 months after it received $100 million in funding.\nThe company would not confirm how many workers were cut in the layoffs.\n\nJuly 6:\n\nSumitomo Pharma America plans to lay off 62 employees from its New York City\noffice previously owned by its subsidiary Sumitovant Biopharma, according to a\nWARN notice published July 3. The company stated the layoffs are a result of\nits effort, previously announced in April, to combine its seven subsidiaries\ninto one company dubbed Sumitomo Pharma America.\n\nJuly 5:\n\nZymergen plans to lay off three workers in Alameda County, CA, effective Aug.\n1, according to a California WARN report. The company was acquired by Ginkgo\nBioworks in July 2022, and this most recent filing marks the fourth round of\nlayoffs it has implemented since.\n\n## June\n\nJune 30:\n\nBellerophon Therapeutics is laying off \"substantially all\" of its staff,\naccording to an SEC filing. The cuts include the company's C-suite. This\nfollows a June 5 announcement that its only clinical program had come to a\nhalt after failing to meet its primary endpoint in fibrotic interstitial lung\ndisease.\n\nEiger BioPharmaceuticals is cutting 25% of its workforce and shifting its\nfocus to to a GLP-1 antagonist being developed to treat metabolic diseases. As\npart of the restructuring, the company will also stop R&D spending for a liver\ndisease candidate.\n\nJune 27:\n\nIllumina has begun layoffs in San Diego in an effort to cut annual expenses by\n$100 million by the end of 2023, according to an SEC filing. No WARN report\nhas been filed as of this writing, and the company declined to confirm how\nmany workers were being laid off, according to The San Diego Union-Tribune.\n\nJune 26:\n\nIntercept Pharmaceuticals announced it is abandoning its NASH program and\nlaying off about one-third of its workforce. This came one day after the FDA\ndenied the application for its obeticholic acid tablets to treat patients with\npre-cirrhotic liver fibrosis due to non-alcoholic steatohepatitis. Intercept\nexpects the cuts to save it about $140 million a year.\n\nJune 22:\n\nFederation Bio confirmed to Fierce Biotech that it has laid off an undisclosed\nnumber of workers just six months after launching its first Phase I trial. The\ncompany did not disclose the reason for the layoffs.\n\nJune 21:\n\nNutcracker Therapeutics has laid off 12 employees, a company spokesperson\nconfirmed to Fierce Biotech. The spokesperson added that the cuts were made in\nan attempt to focus on its three preclinical programs, emphasizing that the\ncompany has no plans to cut any of the programs at this time.\n\nJune 20:\n\nThermo Fisher Scientific plans to cut 88 workers in the San Diego area,\naccording to a WARN notice filed in California. This news came two months\nafter it announced plans to close three sites in San Diego. This brings Thermo\nFisher\u2019s total number of job cuts in the area to nearly 600 since the start of\n2023.\n\nMolecular Templates is laying off 44% of its workforce as part of a\nrestructuring initiative to save cash flow and potentially find a buyer,\naccording to a June 16 press release. This round of cuts follow a March\nannouncement that the company was cutting approximately half of its staff.\n\nTwist Bioscience is laying off 212 employees in California, according to WARN\nnotices filed with the state. The majority of the cuts will take place in San\nFrancisco. These layoffs are part of a restructuring initiative the company\nannounced in May that includes cutting about 25% of its total workforce.\n\nJune 14:\n\nEncoded Therapeutics is cutting approximately 10% of its headcount in an\neffort to extend cash flow into 2026, chief business officer David McNinch\ntold Fierce Biotech. He declined to confirm how many staffers were affected,\nbut he said the cuts were part of an effort to shift its focus to getting its\nlead asset, a treatment for Dravet syndrome, through the clinic.\n\nJune 12:\n\nRejuvenate Bio Bio has cut a \"sizable portion\" of its staff and made cuts to\nits pipeline, Endpoints News reported. A Rejuvenate spokesperson confirmed to\nthe news organization that it was in fact making cuts, but it did not specify\nhow many staffers would be affected by the layoffs.\n\nJune 5:\n\nGreenLight Biosciences is laying off 96 members of staff, effective July 29,\naccording to a WARN notice received by the state on May 31. News of the cuts\ncomes shortly after the company announced it had agreed to be acquired by a\ngroup of buyers led by Fall Line Capital, LLC.\n\nJune 2:\n\nOncorus is laying off 55 employees, or \u201csubstantially all\" of its workforce,\naccording to a post-market release. The cuts include CEO Ted Ashburn, COO\nStephen Harbin and CMO John Goldberg. Interim CFO Alexander Nolte will remain\nin order to attempt to find a buyer for the biotech before it runs out of\ncash.\n\nRoche plans to sell a drug manufacturing plant in Vacaville, CA, or shut the\nfacility down by 2029, according to an internal email sent Wednesday obtained\nby Reuters. The plant currently employs 800 staff members, and though Roche\nwould not confirm any details about the timeline or number of employees\naffected to Reuters, it did confirm plans to sell the site.\n\nCatalent plans to lay off 150 employees from its Bloomington, IN plant by\nFriday, Indiana Public Media reported, according to an internal email sent to\nemployees. A company spokesperson told the news outlet that the cuts will\nmainly affect leadership and support positions, and come as part of a\nrestructuring due to difficulty sustaining the growth the company saw during\nthe COVID-19 pandemic.\n\n## May\n\nMay 31:\n\nRain Oncology is laying off 65% of its staff, including its chief medical\nofficer. This news came one week after the company's lead candidate,\nmilademetan, fell short in a Phase III liposarcoma trial. Rain is also pausing\na Phase II trial and dropping another Phase I/II trial completely, both\nstudying milademetan.\n\nMay 24:\n\nTakeda plans to lay off 27 employees in San Diego two weeks after giving\nnotice of plans to lay off more than 180 employees in Massachusetts. A Takeda\nspokesperson told BioSpace that the cuts in California are directly related to\nthe company\u2019s decision to discontinue discovery and pre-clinical efforts in\nAAV gene therapy and in rare hematology.\n\nPTC Therapeutics, Inc. has implemented a pipeline prioritization initiative,\nthat includes dropping several preclinical and early-phase R&D projects in\ngene therapy and an 8% reduction in its workforce.\n\nMay 23:\n\nAffimed cut about 25% of its total headcount in April, according to the\ncompany's Q1 earnings report. These cuts came as part of a restructuring\neffort in which the company hopes to prioritize the three clinical programs in\nits pipeline.\n\nMay 19:\n\nUrovant Sciences is laying off 22 employees, effective June 29, according to a\nCalifornia WARN notice filed in April and published in May. This news comes\njust a few weeks after the company revealed that it is being folded into its\nparent company, Sumitomo, along with six other sister companies.\n\nMay 16:\n\nGeneDx, a clinical genomics and genetic testing company, is laying off 19\nemployees beginning May 28, according to a Connecticut WARN notice. This comes\nafter the company cut 700 jobs last year. The most recent cuts include only\nremote employees, CT Insider reported.\n\nMay 11:\n\nAdaptive Phage Therapeutics, Inc. cut 22 jobs, or 23% of its total headcount,\nto shift its focus to its clinical trials and extend its cash runway, the\nWashington Business Journal reported. The layoffs went into effect on May 9.\n\nMay 10:\n\nRoche has cut 165 jobs in Branchburg, New Jersey\u2014the home of its largest\ndiagnostic operations center in the U.S. The layoffs will go into effect on\nJuly 25, according to a Worker Adjustment and Retraining Act (WARN) notice\nfiled in April.\n\nMay 9:\n\nNovavax is cutting its global workforce by about 25%, according to its first-\nquarter earnings report. The layoffs include about 500 of the nearly 2,000\nemployees that Novavax cited in its 2022 annual report.\n\nGossamer Bio announced plans to lay off 25% of its workforce as part of an\neffort to shift its focus to its pulmonary arterial hypertension (PAH)\ncandidate, which is set to enter Phase III in the third quarter of this year.\nThe biotech stated it plans to cut all clinical and preclinical programs other\nthan the PAH candidate.\n\nADC Therapeutics plans to cut about 17% of its staff\u2014about 54 employees in\ntotal\u2014along with two preclinical programs. This news follows disappointing\nsales for Zynlonta, an ADC approved to treat diffuse large B cell lymphoma.\n\nMay 8:\n\nTakeda plans to lay off about 186 employees in Massachusetts, according to a\nWARN report. The cuts will affect employees in four locations across three\ncities in Massachusetts: Cambridge, Lexington and North Reading.\n\nBristol Myers Squibb plans to lay off 48 staff members from its Princeton, New\nJersey, facility, according to a WARN notice filed in April. Though no other\ninformation was provided in the WARN report about which divisions will be\naffected, the facility houses employees from the commercial, R&D and enabling\nfunction support teams, according to the company\u2019s website.\n\nEQRx announced plans to cut 170 jobs and several drug candidates as part of a\nrestructuring effort. The startup was formed to develop an affordable\nalternative to name-brand prescription drugs, but tight FDA regulations forced\nthe company to pivot.\n\nMammoth Biosciences cut 35 jobs in March, Mammoth CEO Trevor Martin confirmed\nto Endpoints News. The biotech is looking to ditch its efforts in CRISPR\ndiagnostics and shift its focus to therapeutic research.\n\nMay 4:\n\nSelecta Biosciences announced plans to cut about 25% of its workforce as part\nof an effort to implement a \"capital prioritization initiative,\" according to\nits Q1 financial report. The cuts are expected to extend the company's cash\nflow to the second half of 2025.\n\nMay 3:\n\nZymergen plans to lay off 27 members of staff in Alameda County, CA, effective\nJune 20, according to a California WARN report. The company was acquired by\nGinkgo Bioworks in July 2022, and this most recent filing marks the third\nround of layoffs it has implemented since.\n\n## April\n\nApril 27:\n\nTransplant Genomics has cut nine remote workers from its staff, according to a\nMassachusetts WARN report. The report was filed on April 27, and the layoffs\nwent into effect the very next day.\n\nSumitomo plans to lay off a combined 122 members of staff from both Sumitomo\nPharma America Holdings and Sumitomo Pharma Oncology in Massachusetts. It will\nalso cut 101 jobs from subsidiary Sunovion Pharmaceuticals. This news comes\none month after the pharma announced plans to consolidate its many\nsubsidiaries into one company, Sumitomo Pharma America.\n\nCepheid, a company known for making rapid coronavirus tests, plans to cut 625\nmembers of staff in the California Bay Area, according to a WARN report. This\nis the company's second round of layoffs in the last six months. In November,\nthe company announced plans to cut 925 jobs, also in the Bay Area.\n\nCare Access, a contract research startup, has cut about half of its headcount,\naccording to a LinkedIn post by CEO and co-founder Ahmad Namvargolian. This\nnews comes just two months after Pfizer cut the startup from its study of a\nLyme disease vaccine.\n\nApril 26:\n\nThermo Fisher Scientific plans to lay off 218 workers related to the closing\nof three facilities in San Diego, according to a WARN report. This is the\nthird round of layoffs the company has implemented in San Diego so far this\nyear, and this most recent round brings the total number of cuts in the area\nto just over 500. In March, Thermo Fisher also announced plans to close a New\nJersey manufacturing site and lay off 113 employees.\n\nSangamo Therapeutics announced plans to layoff about 120 staff members\n(approximately 27% of total workforce) as part of a restructuring effort. This\nnews comes only one month after both Novartis and Biogen ended their\npartnerships with the biotech.\n\nEvelo Biosciences announced it is cutting its workforce and dropping an atopic\ndermatitis program in an effort to extend its cash flow. This is the company's\nsecond round of layoffs in three months. The company did not specify how many\njobs would be cut.\n\nApril 20:\n\nFoundation Medicine, Inc., a Roche subsidiary, plans to cut about 135 members\nof staff, according to an April 4 blog post written by CEO Brian Alexander on\nthe company's website. Alexander said the layoffs are part of a decision to\nadopt a \"leaner, more streamlined organizational structure.\"\n\nEnzyvant Therapeutics plans to lay off 20 employees in North Carolina,\nincluding some executive positions, the Triangle Business Journal reported.\nThe WARN notice, filed April 20, stated the cuts are a \"result of the\nintegration of Enzyvant and a number of its affiliates into one new company.\"\n\nApril 17:\n\nEmerald Cloud Lab plans to lay off 30 employees from its headquarters in South\nSan Francisco, effective April 30, according to a WARN report. These cuts\ncould be part of the company's plans to relocate to a new facility in Austin,\nTX, which is expected to open in July.\n\nNektar Therapeutics plans to implement a restructuring initiative that\nincludes cutting its workforce in San Francisco by about 60%. The company said\nit will shift its focus to its immunology portfolio, and the cuts will help\nextend its cash flow to mid-2026.\n\nApril 14:\n\nTalaris Therapeutics plans to lay off about 80 employees, including much of\nits C-suite. In total, the cuts include about 95% of the company's headcount.\nThis follows Talaris' February decision to cut about one-third of its staff\nand axe two clinical trials.\n\nApril 12:\n\nAeglea Biotherapeutics announced plans to lay off all but about 10 members of\nits staff as part of a restructuring initiative. This announcement followed\nmixed interim data from an ongoing Phase I/II study of its classical\nhomocystinuria candidate pegtarviliase.\n\nOncocyte Corporation announced plans to cut its workforce by about 20% in an\neffort to extend its cash flow into 2024. The company did not give a reason\nfor the layoffs in the press release, stating only that the cuts were part of\nan effort to reduce costs and optimize efficiency.\n\nGentiBio, Inc has laid off an undisclosed number of employees, CEO Adel Nada\ntold the Boston Business Journal. The CEO called the cuts \"relatively small,\"\nand cited \"a challenging biotech macroenvironment\" as the reason for the cuts.\n\nApril 10:\n\nBiogen is laying off an unspecified number of employees, according to a report\npublished Monday by the Boston Business Journal. A Biogen spokesperson\nconfirmed the layoffs in an email to BioSpace but declined to reveal the exact\nnumber of affected employees.\n\nApril 7:\n\nPear Therapeutics has filed for Chapter 11 bankruptcy and is seeking to sell\noff its assets, according to an SEC filing. 170 employees (about 92% of total\nstaff) will be laid off as a result, leaving 15 employees who will continue\nworking until the company\u2019s assets are sold.\n\nApril 6:\n\nThermo Fisher Scientific plans to shutter a New Jersey manufacturing facility\nand cut 113 members of staff as a result, according to a WARN report filed in\nMarch. This is the third round of layoffs the company has announced this year.\nSince February, it has cut over 350 staff members, all from manufacturing\nfacilities in San Diego.\n\nLumiraDx, a diagnostics testing solutions company, announced plans to initiate\na restructuring program that includes cutting its headcount by about 40%. The\ncompany expects to save about $36 million a year as a result.\n\nApril 3:\n\nNGM Biopharmaceuticals is implementing a restructuring initiative that\nincludes cutting 75 employees, which make up about 33% of the company's total\nworkforce, according to an SEC filing. CEO David Woodhouse stated the cuts are\nrelated to the Phase II CATALINA trial failure in October 2022.\n\n## March\n\nMarch 31:\n\nMolecular Templates is cutting about half of its staff, leaving it with just\nover 100 employees, according to an SEC filing. The layoffs are the result of\nan effort to narrow its pipeline to only three programs and a preclinical\npartnership with BMS.\n\nMarch 28:\n\nAlector plans to cut about 30 members of staff to focus its resources on\nresearch. In an SEC filing, the company stated this will allow it to\nprioritize its immuno-neurology programs.\n\nApplied Molecular Transport, Inc. (AMT) is slashing its workforce by\napproximately 57%, according to a March 28 announcement. Tahir Mahmood, Ph.D.\nwill step down as CEO and be replaced by President and COO Shawn Cross.\n\nSatsuma Pharmaceuticals announced plans to lay off 36% of its staff, starting\nMarch 31. effective this Friday. This comes after the company announced\nresults from a Phase III trial studying its migraine treatment, STS101, and\nsubmitted an NDA to the FDA earlier this month.\n\n9 Meters Biopharma announced it is cutting about half of its workforce in an\neffort to extend its cash runway. The announcement came as part of its fourth-\nquarter financial report.\n\nMarch 23\n\nMerck KGaA's EMD Serono plans to cut six members of staff research center in\nBillerica, MA, beginning May 22, according to a Massachusetts WARN report. In\nJanuary, the company announced plans to cut 133 employees from the same\nlocation as part of a plan to prioritize R&D and rely more heavily on its\npartnerships for drug development.\n\nGenentech, Inc. plans to close a production facility in South San Francisco,\nCA. As a result, 271 employees will be laid off, according to the WARN report.\n\nMarch 20\n\nFerring Pharmaceuticals is closing its research facility in San Diego, CA and\nlaying off 89 employees as a result. According to a WARN notice filed with the\nstate of California, the layoffs will be effective May 26.\n\nEvofem Biosciences is cutting eight staff members just four months after\ncutting 39 jobs. The company also plans to cut its CEO's salary by 40% in an\neffort to save cash.\n\nMarch 16\n\nAmgen is cutting 450 members of its workforce, according to a Reuters report.\nThis is Amgen's second round of layoffs this year; the first, in January,\nincluded 300 members of staff.\n\nMarch 15:\n\nVaxart, Inc. plans to reorganize its pipeline to prioritize its oral norovirus\nvaccine program and push back clinical trials for its COVID-19 vaccine. The\nreorganization includes cutting about 27% of staff in an effort to extend cash\nflow into 2024.\n\nMarch 9:\n\nOlema Oncology announced it is shifting its focus to advancing OP-1250, a\ntreatment for ER+/HER2- metastatic breast cancer, into Phase III. The\nrestructuring will include cutting about 25% of its workforce.\n\nMarch 8:\n\nNeoleukin Therapeutics announced it is reviewing strategic alternatives that\ncould include a sale, merger, divestiture of assets, licensing or other\nstrategic transaction. As a result, the company is cutting 70% of its\nworkforce in the first half of 2023.\n\nMarch 7:\n\nThermo Fisher Scientific is laying off 154 people in San Diego, according to a\nWARN report. This news comes just one month after it announced plans to lay\noff 230 employees at three manufacturing sites in San Diego. The company cited\nreduced demand for COVID-19 testing kits as the reason for both rounds of\ncuts.\n\nMarch 6:\n\natai Life Sciences announced it has cut staff by about 30% as part of a in\norder to extend its cash runway into the first half of 2026. The company\nstated the decision came after a strategic review of its pipeline in an effort\nto enhance efficiency and narrow its focus.\n\nCoherus BioSciences announced in its fourth-quarter report that it has cut\nabout 60 full-time and part-time employees from its payroll as part of a\nrestructuring initiative. The company's operating expenses for this year are\nnearly $100 million lower than those projected in April 2022.\n\nMarch 2:\n\nMorphoSys AG plans to drop its pre-clinical programs and cut 17% of its\nworkforce to extend its cash runway. The cuts will take place at the company\u2019s\nPlanegg headquarters, and a total of 70 employees will lose their jobs.\n\nMarch 1:\n\nNovo Nordisk is laying off 86 employees in Seattle, effective May 1, according\nto a WARN notice. A spokesperson told GeekWire that the company is shuttering\nits Seattle-based wet lab operations, but that it will continue its efforts in\ndigital therapy, data science and AI in the area.\n\nG1 Therapeutics released its full-year 2022 financial report that stated it\nhas cut its headcount by about 30% to reduce operating expenses in 2023. This\ncomes two weeks after the biotech ended a late-stage study of its lead\ncandidate in colorectal cancer, causing shares to plunge 50%.\n\n## February\n\nFeb. 28:\n\nTheravance Biopharma is discontinuing research activities for its JAK\ninhibitor program in lung inflammation and reducing its headcount by about\n17%. The strategic realignment folows a letter from one of Theravance\u2019s\nlargest shareholders, Irenic Capital, urging the company to review its\ngovernance structure and reassess its business strategies.\n\nFeb. 24:\n\nObsEva, a women's health biotech based in Switzerland, is cutting several\nstaff members from its executive team in the U.S. and its board of directors.\nThese cuts include the company's CEO, CMO and several others.\n\nFeb. 22:\n\nGraphite Bio announced it is discontinuing the development of nulabeglogene\nautogedtemcel (nula-cel), its lead asset. Simultaneously, the Bay Area biotech\nis launching a corporate restructuring program that will shave off about 50%\nof its workforce.\n\nImpel Pharmaceuticals is implementing a restructuring initiative that includes\ncutting staff by 16%. It plans to drop its INP105 treatment for acute\nagitation and aggression in autism spectrum disorder and focus on developing\nits Trudhesa nasal spray.\n\nJounce Therapeutics announced plans to merge its business in an all-stock deal\nwith clinical-stage biotech Redx Pharma. This news came one day after the\nbiotech announced a restructuring plan that included cutting 57% of staff.\n\nFeb. 21:\n\nNational Resilience Inc. announced plans to sell a manufacturing site in\nMarlborough, MA and scale back operations at another in Allston, MA. The\ndecision will result in about 213 job cuts in total.\n\nAileron Therapeutics announced it plans to drop its its lead candidate,\nALRN-6924, after it did not meet the primary or secondary endpoints in a Phase\n1b trial studying the candidate in breast cancer patients. As a result, the\ncompany will cut its staff from nine employees to three.\n\nFeb. 15:\n\nGrifols announced a comprehensive plan to save money and resources that will\nresult in 2,000 U.S. job cuts. The company stated its goal is to save\napproximately $428 million USD in 2023.\n\nFeb. 13:\n\nFrequency Therapeutics is cutting 55% of its workforce due to its decision to\ndrop all programs designed to treat Sensorineural Hearing Loss (SNHL). This\ncomes after its candidate, FX-322, did not meet the primary endpoint in SNHL\npatients in a Phase IIb trial.\n\nFeb. 9:\n\nEliem Therapeutics is dropping a depression drug candidate that was heading\ninto Phase II and laying off 55% of staff in an attempt to stretch its cash\nrunway into 2027.\n\nFeb. 8:\n\nAligos Therapeutics announced it has implemented a pipeline reprioritization\nresulting in a staff reduction of about 25%. The biotech will now prioritize\nits NASH and COVID-19 assets, including its NASH collaboration with Merck.\n\nFeb. 6:\n\nThermo Fisher Scientific will cut a total of 230 jobs at three sites in San\nDiego County, CA. This comes after the pharma reported a significant drop in\nsales of its COVID-19 tests in 2022.\n\nMagenta Therapeutics is cutting up to 56 positions from its workforce - about\n84% of its total staff - according to a filing with the SEC. This comes days\nafter the biotech suspended the development of its clinical programs after a\npatient's death halted a Phase I/II trial.\n\nFeb. 3:\n\nEisai Inc. filed a WARN notice with the state of New Jersey that stated it\nplans to cut 91 jobs. The job cuts will be effective on April 30.\n\nVyant Bio announced plans to cut its workforce in an attempt to extend its\ncash runway, though the announcement did not specify how many jobs would be\ncut. The decision is due to leadership's belief that \"its stock price does not\nreflect the fundamental value of the business.\"\n\nMedicago, a plant-based COVID-19 vaccine developer, announced it will shut its\ndoors due to a slowdown in the COVID-19 pandemic. This follows the company's\nNovember announcement that it planned to lay off 62 employees at a North\nCarolina manufacturing facility.\n\nFeb. 1:\n\nEvelo Biosciences announced it has implemented cost-saving initiatives that\ninclude an unspecified amount of job cuts. In the same announcement, the\ncompany also stated its atopic dermatitis candidate, EDP1815, did not meet its\nprimary endpoint in a Phase II trial.\n\n## January\n\nJan. 31:\n\nInstil Bio plans to cut its staff to just 15 employees in an attempt to extend\nits cash runway through 2026. This additional reduction follows the company's\nDecember announcement that it planned to cut staff by 60%.\n\nINOVIO announced plans to reorganize its pipeline to prioritize \"operational\nefficiency\" and cut staff by 11%. By cutting several programs, the company\nexpects to save about $3.4 million.\n\nJan. 30:\n\nQuince Therapeutics plans to reprioritize its pipeline and lay off 47% of its\nstaff, according to an SEC filing. The new strategy follows the company's\ndecision to sell its protease inhibitor portfolios.\n\nAmgen is implementing organizational changes that include laying off\napproximately 300 team members to \u201cbetter manage against industry headwinds,\u201d\na company spokesperson confirmed to BioSpace. The job cuts will mainly affect\nAmgen\u2019s commercial team and will involve employees based in the U.S., the\nspokesperson said.\n\nJan. 24:\n\nFinch Therapeutics announced it plans to discontinue the Phase III trial of\nits main asset, a bacterial infection drug dubbed CP101. As a result, it will\ncut about 95% of its workforce. Finch cited a lack of funding and partnerships\nto develop the drug as the reason behind the decision.\n\nJan. 23:\n\nMerck KGaA's EMD Serono plans to cut 133 members of staff at its research\ncenter in Billerica, MA. This comes a few months after the biotech announced\nit planned to prioritize R&D and rely more heavily on its partnerships for\ndrug development.\n\nJan. 19:\n\nReNeuron announced plans to restructure and cut staff by 40% as in an effort\nto stretch its cash flow until 2024. This comes two weeks after Catherine\nIsted resigned from her role as CEO.\n\nCyteir Therapeutics announced a restructuring initiative focused on\nprioritizing CYT-0851, an investigational monocarboxylate transporter\ninhibitor being studied in ovarian cancer. The shift will result in a 70%\nreduction in staff.\n\nJan. 12:\n\nAkili Interactive Labs announced that due to the recent shift in the economic\nenvironment, it will reduce its staff immediately by approximately 30%,\ncutting 46 employees in total.\n\nJan. 11:\n\nVerily Life Sciences, a unit of Alphabet Inc. formerly known as Google Life\nSciences, plans to undergo a restructuring that includes cutting about 15% of\nits workforce - over 200 jobs in total.\n\nAbzena laid off 66 employees from its San Diego, CA location, according to a\nWARN notice filed with the state of California.\n\nJan. 9:\n\nCalithera Biosciences' board of directors has decided to dissolve the company\nand liquidate its assets, and most employees will be let go by the end of Q1.\nIn 2021, Calithera bought two Phase II cancer assets from Takeda in an attempt\nto bounce back, but it announced in November that data from the assets had\nbeen delayed.\n\nEditas Medicine announced it has cut 20% of staff, including Chief Scientific\nOfficer Mark Shearman, Ph.D, in a pipeline reorganization. This follows the\ncompany's November announcement that it planned to press pause on its lead\nasset, EDIT-101, due to disappointing data.\n\nJan. 6:\n\nElevation Oncology has cut 30% of its staff, including CEO Shawn Leland. As\npart of the restructuring, Elevation has also decided to shelf seribantumab,\nits solid tumor therapy.\n\nJan. 5:\n\nCentury Therapeutics announced it plans to lay off 25% of its staff in order\nto extend cash flow for three candidates: CNTY-101 and CNTY-102 for B-cell\nmalignancies and CNTY-107 for solid tumors.\n\nJan. 4:\n\nY-mAbs Therapeutics stated it will implement a restructuring plan that\nincludes reducing its workforce by 35% by the end of May. The biotech stated\nit plans to prioritize Danyelza, its treatment for relapsed/refractory, high-\nrisk neuroblastoma.\n\n## December 2022\n\nDec. 15:\n\nAthenex Pharma Solutions filed a WARN notice with the state of New York\nstating it plans to close a production facility in Clarence, NY, laying off 92\nemployees as a result. The company stated the decision was due to financial\ndifficulty, though it did not specify the cause.\n\nAxcella Therapeutics announced that in an effort to reprioritize its\nresources, it will prioritize its Long COVID program and slash its headcount\nby 85%.\n\nDec. 9:\n\nTherapeuticsMD, Inc. filed a notice with the state of Florida that stated it\nplans to lay off its entire workforce, totaling 212 employees.\n\nDec. 8:\n\nInstil Bio announced it is discontinuing the development of its unmodified\ntumor-infiltrating lymphocyte (TIL) therapeutic, ITIL-168, and laying off 60%\nof its staff.\n\nNeil Versel is the business editor at BioSpace. You can reach him at\nneil.versel@biospace.com. Follow him on LinkedIn or X.\n\n### Most Read Today\n\n  * EMA Finds No Link Between GLP-1 Drugs and Suicidal Thoughts, Self-Harm\n  * EC Approves Illumina\u2019s Plan to Divest Cancer Diagnostics Maker Grail\n  * AstraZeneca Expands Fasenra\u2019s Label to Younger Children with Severe Asthma\n  * Fujifilm Pumps $1.2B into CDMO Capacity in North Carolina, Eyes 680 New Jobs by 2031\n  * CryoEM: Evolution and Best Practices\n\n  * Email this\n  * Facebook\n  * Twitter\n  * LinkedIn\n  * Pinterest\n  * Reddit\n\nBack to news\n\nBack to top\n\n\u00a9 1985 - 2024 BioSpace.com. All rights reserved. Powered by Madgex Job Board\nSoftware\n\n", "frontpage": false}
